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Background. Exposures to organophosphate esters (OPEs), common-use plasticizers/flame 
retardants, are widespread in contemporary human populations. OPEs have been suggested as thyroid 
disruptors, although inconsistencies exist and research is sparse in vulnerable populations. Particularly 
during early pregnancy, maintaining normal maternal thyroid function is critical to fetal brain 
development. Neurodevelopment in children has also been linked with OPEs, specifically more 
hyperactivity and attention problems. These behaviors are often found in children with attention-deficit 
hyperactivity disorder (ADHD), however, prenatal OPE exposures have not been evaluated as risk factors 
for ADHD.  
 Methods. A case-cohort study was nested within the Norwegian Mother, Father, and Child 
Cohort. Four OPE metabolites were measured from maternal urine collected at 17 weeks’ gestation. We 
also considered 6 urinary phthalate metabolites, given their potential to co-occur with OPEs. In Aim1, the 
sub-cohort was used to cross-sectionally investigate the relationship between exposure to common-detect 
OPEs and phthalates and 6 maternal thyroid function biomarkers in euthyroid pregnant women, using 
Bayesian Kernal Machine Regression (BKMR) and general linear regression (GLM). In Aim2, a case-
cohort analysis was conducted to estimate the risk ratios (RRs) associated with elevated individual and 
joint exposure(s), using logistic regression and quantile based g-computation, respectively. Mediation 
through maternal thyroid function and effect measure modification by child sex and polymorphisms in 
metabolism enzymes were explored.  
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Results. Diphenyl phosphate (DPHP) and di-n-butyl phosphate (DNBP) were commonly 
detected; while bis(2-butoxyethyl) hydrogen phosphate and bis(1,3-dichloro-2-propyl) phosphate 
(BDCIPP) were detected infrequently. In Aim 1, DPHP was inversely associated with total 
triiodothyronine to total thyroxine ratio in GLM, although the associations near-null in BKMR. In Aim 2, 
elevated risk of ADHD was observed with pregnancy exposure to greater than sub-cohort median DPHP 
(RR: 1.38 [95% confidence interval: 0.96, 1.99]) and BDCIPP detection (1.50 [0.98, 2.28]). For DPHP, 
we observed weak mediation through pregnancy maternal thyroid function and suggestive modifications 
by polymorphisms and child sex. A quartile reduction in combined exposure to DPHP, DNBP, and 
phthalate metabolites resulted in an RR of 0.68 [0.64, 0.72]. 
Conclusions. Prenatal exposure to DPHP and BDCIPP may increase the risk of ADHD. Thyroid 
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CHAPTER 1. INTRODUCTION AND SPECIFIC AIMS 
 
1.1. Introduction 
Organophosphate esters (OPEs) are increasingly produced and used as plasticizers and/or flame 
retardants1 since regulations were placed on a class of conventional persistent flame retardants in the early 
2000s2, 3, i.e., polybrominated diphenyl ethers (PBDEs). Although less persistent than PBDEs, OPEs do 
not form covalent bonds and therefore easily leach into the surrounding environment1. Consequently, 
metabolites of common-use OPEs are often detected in human populations, such as diphenyl phosphate 
(DPHP), bis(1,3-dichloro-2-propyl) phosphate (BDCIPP), di-n-butyl phosphate (DNBP), and bis(2-
butoxyethyl) hydrogen phosphate (BBOEP)4, 5; however, their impacts on human health and disease are 
not well understood. 
Several experimental studies report thyroid disruptive properties for some OPEs6-8. Although 
epidemiological investigations are relatively sparse, DPHP has been associated with thyroid function in 
sub-fertile men9, 10 and office workers11. Further investigations are warranted in populations that are 
vulnerable to subtle changes in thyroid function, such as pregnant women and the developing fetus. 
Failure to maintain normal thyroid function in pregnant women has been associated with an array of 
adverse health outcomes in mothers and offsprings, such as pregnancy complications and offspring 
neurodevelopment, for example, attention-deficit hyperactivity disorder (ADHD)12-18. 
Neurotoxicity of OPEs has also been reported in experimental19, 20 as well as epidemiological 
investigations21-23. Specifically, higher concentrations of DPHP and BDCIPP during pregnancy have been 
linked with slightly more externalizing behaviors, attention problems, and hyperactivity in offspring21-23. 
Such behaviors are key characteristics of children with ADHD24, which raises the question of “Does OPE 
exposure increase the risk of ADHD?”  
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It is also important to consider the fact that environmental exposures do not occur in isolation. 
For example, human exposure to phthalates, one of the suggested environmental risk factors for ADHD25 
and thyroid dysfunction26, 27, may co-occur with some OPEs28-33. Given the co-occurring nature of 
exposures that are likely confounders, it may be insufficient to characterize relationships using 
conventional models where only a single pollutant is included in the analytic model. 
This dissertation aims to evaluate prenatal exposure to OPEs, including but not limited to DPHP 
and BDCIPP, as a risk factor for offspring ADHD and to examine a potential underlying mechanism of 
maternal thyroid disruption during pregnancy. A case-cohort study was nested within the Norwegian 
Mother, Father, and Child Cohort (MoBa). In Aim 1, a cross-sectional investigation of OPE exposure and 
thyroid function was conducted in euthyroid pregnant women, who were identified as sub-cohort 
members. In Aim 2, a case-cohort study was conducted to evaluate pregnancy exposure to OPEs as a risk 
factor for offspring ADHD. In both aims, the correlated nature of environmental exposures was 
contemplated using the mixtures analytic method that was best suited for each question. Additionally, 
select effect measure modifiers were explored, including single nucleotide polymorphisms (SNPs) that 
can modify the activities of candidate enzymes involved in the metabolism of OPEs.  
 
1.2. Specific Aims and Hypotheses 
 
 Specific Aim 1 
Characterize relationships between OPE metabolites measured in maternal urine and thyroid 
function biomarkers measured in maternal serum, both of which were collected at 17 weeks gestation, 
considering potential confounding by relevant chemicals 
 Specific Aim 2 
Evaluate pregnancy exposure to OPEs as a risk factor for offspring ADHD.  
Sub Aim 1. 1. Explore effect measure modification by SNPs and child sex  




I hypothesize that higher exposure to OPEs in pregnant women will be associated with altered 
thyroid function in mothers during pregnancy and elevated risk of ADHD in offspring. DPHP will be 
most strongly associated with thyroid function and ADHD risk, given the common usage of its parent 
compounds and the findings from previous literature. Associations could be stronger among children 
whose mother has slow-metabolizing SNPs and will persist when considering confounding by correlated 





CHAPTER 2. CRITICAL REVIEW OF LITERATURE  
 
2.1. Organophosphate esters (OPEs) 
 Human exposure to OPEs 
OPEs are a class of plasticizers and flame retardants, which are commonly used in personal care 
and consumer products, such as fragrance34, cosmetics34, nail polish34, polyurethane foams, furniture, 
electronics, flooring1. From these various products, OPEs can easily leach out or volatilize into the 
atmosphere35-37, river38, wastewater37, 39, fish40, food41, indoor air36, and dust indoors or in vehicles36, 42. 
Contact with these residues or their sources results in human exposure. OPE metabolites commonly 
detected in human populations include DPHP, BDCIPP, DNBP, and BBOEP4, 5, 23, 34, 43-47.  
Human exposure to OPEs has been increasing over time, with up to a three-fold increase in 
DPHP and a 16-fold increase in BDCIPP reported in US adults in 2012-2015 as compared to that in 2002-
200348. Elevated DPHP in the previous study is reflective of the increased use of its parent compounds: 
including triphenyl phosphate (TPHP)49, resorcinol bis-diphenyl phosphate50, and ethylhexyl diphenyl 
phosphate49. Detection of DPHP and BDCIPP is not limited to the US and has been reported worldwide 
(Table 1). The specific OPE metabolite most prevalent in urine varies by country (Table 1), which is 
likely due to the country-specific usage patterns of OPEs. DNBP and BBOEP have been commonly 





Table 1 Median urinary concentrations (ng/ml) of commonly detected OPE metabolites in women (specific gravity standardized geometric mean in 
parenthesis) 
Author, year N Time Place Average age 
(man-max) 
Gestational weeks DPHP BDCIPP DNBP BBOEP 
Pregnant Women         
Current 555 2003-2008 Norway       
Romano, 201743 59 2014-2015 RI, US 29. 5 ± 4. 5 12 0.86 1.09 . . 
28 1.06 1.39 . . 
Feng, 201644 23 2015 China (25-40) 2nd trimester 0.83 1.58 . . 

















Kosarac, 201645 24 2010-2012 Canada (18-45) 2-3rd trimester 2.94 0.26 . <LOD [0.08] 










Women undergoing IVF cycles       





Mothers from mother-child dyads      





Ospina, 201854 22 2013-2014 NJ, US (18-) .  (1.9) (2.4) . . 








Females from NHANES        
Su, 20155 2666 2013-2014 US (6-) .  0.89 0.82 0.24 . 
*DPHP: Diphenyl phosphate; BDCIPP: bis (1, 3-dichloro-2-propyl) phosphate; BBOEP: bis (2-butoxyethyl) hydrogen phosphate; DNBP: di-n-butyl 






 OPE metabolism in humans 
DPHP, BDCIPP, DNBP, and BBOEP are major diaryl or dialkyl phosphates that can result from 
phase-I metabolism of TPHP49, 55-57, tris(1,3-dichloro-2-propyl)phosphate (TDCIPP)55, 58, tributyl 
phosphate (TNBP)59, and tris(2-butoxyethyl) phosphate (TBOEP)55, 59, 60, respectively (Figure 1). These 
diaryl/dialkyl phosphates can be further metabolized into monoaryl/monoalkyl phosphates. Alternatively, 
OPEs can be metabolized into different types of triaryl/trialkyl phosphates, which can then undergo 
phase-II conjugation. Although the specific enzymes responsible for each OPE metabolic pathway have 
not been identified in humans, in vitro studies observed that human liver microsomes55, 60, human liver s9 
fractions55, and human serum60 can break down OPEs into phase-I and phase-II metabolites. Enzymes 
abundant in human liver or serum, specifically cytochrome P450 (P450) enzymes and paraoxonases, are 
candidate enzymes for the phase-I metabolism of OPEs (Figure 1) in light of their established role in 
xenobiotic metabolism61-63 and experimental studies supporting altered enzymatic activities in bacteria64, 
65. 
 P450 enzymes are a group of xenobiotic-metabolizing enzymes that are abundant in the human 
liver66. Human P450 enzymes are involved in a majority of the metabolic pathways reported for 
xenobiotic and natural chemicals (95% of the reactions published 1976-200867). A systematic review 
classified CYP1A2 as the most common P450 enzyme (15%) involved in the metabolism of general 
chemicals67. CYP1A2 catalyzes phase-I metabolism of xenobiotics such as caffeine68, melatonin69, and 
organophosphate pesticides70, 71 (Table 2). Additionally, an experimental study on Brevibacillus brevis 
reported the potential for P450 enzymes to catalyze the breakdown of TPHP64. Brevibacillus brevis 
degraded TPHP into DPHP, however, the addition of a P450 inhibitor (i.e., piperonyl butoxide) decreased 
the TPHP degradation and P450 gene expression64. Collectively, these previous studies point to P450 






a) TPHP (an example of aryl-OPEs) 
    
b) Alkyl-OPEs (e.g., TnBP and TBOEP) 
                     
c) Chloride-contained OPEs (e.g., TDCIPP) 
             
Figure 1 Metabolic pathways of (a) aryl, (b) alkyl, and (c) chloride-contained OPEs and their metabolites 
(the metabolite measured in the current study boxed in purple). Enzymes potentially catalyzing phase I and 





Paraoxonases are another group of enzymes that may catalyze OPE metabolism. They are 
calcium-dependent hydrolytic enzymes that are abundant in human serum72. Organophosphate pesticides, 
including parathion, are well-known substrates for paraoxonase 1 (PON1)63. Parathion, upon entering the 
human body, is metabolized into a biologically active intermediate, paraoxon, which contains three 
phosphorus-oxygen (P-O) bonds. One of the P-O bonds in paraoxon is hydrolyzed under the presence of 
PON1, turning paraoxon into a diethyl phosphate and a byproduct. Similarly, TPHP contains three P-O 
bonds, where one P-O bond is broken to form a diaryl phosphate (i.e., DPHP) and a byproduct is formed 
under the presence of serum hydrolase49. The potential for PON1 to catalyze OPEs is also supported by an 
experimental study that observed the breakdown of OPEs by Sphingobium species strain TCM1, which 
has active sites similar to PON165. Therefore, PON1 is a plausible candidate that can catalyze the 
breakdown of TPHP into DPHP in humans.  
The enzyme activity and/or concentrations of CYP1A2 and PON1 are influenced by their 
functional polymorphisms (Table 2). SNPs of CYP1A2 can modify smoke-induced enzyme activity73 and 
metabolic rates of caffeine68 and melatonin69. SNPs of PON1 can modify plasma concentrations        
(-108C/T74; L55M63), and substrate-specific enzyme activity (Q192R63). Such gene-induced differences in 
the expression or function of CYP1A2 and PON1 may influence the formation or excretion of OPE 
metabolites since these enzymes could catalyze OPEs’ metabolism (Table 2). Individuals with SNPs that 
contribute to a slow breakdown of OPEs may be exposed to OPE metabolites for a longer duration, 
compared to those with SNPs that contribute to rapid metabolism, placing them at higher vulnerability to 
the potential effects of OPE exposures75, 76.  
 
 
Table 2 Reported characteristics of single nucleotide polymorphisms (SNPs), including dominant allele frequency in Europeans (Genome 














Environmental risk factors modified 
by SNPs 
PON1      
  L55M 




- Lower PON1 plasma levels in M5563, 77 
- Linkage disequilibrium with -108T 
DPHP Paraoxon77 GIS-based organophosphate pesticide 
use – cognitive scores (Mini-Mental 
State Exam) association strongest in 
55MM (TT78) 
  Q192R 
  (rs662) 
T>C (72.0) 





Stronger PON1 activity  
in R192 for oxon substrates, including 
paraoxon63, 77 
DPHP Paraoxon77 - MeHg-neurodevelopment* 
association stronger in CC/TC79 
- Total dialkylphosphate-
neurodevelopment association 
stronger in mothers with QR/RR75 
- Total dialkylphosphate-decreased 
head circumference association 
observed in children with QQ80 
- Frequent organophosphorus 
pesticide use – PD association 
strongest in QQ81   
CYP1A2      
  -1545C/T    
  (rs2470890) 
T>C (63.7) - Smoke-induced enzyme activity ↑ in 
CYP1A2*1F(-163 A/A)73 
- Metabolism of melatonin ↓ in 
CYP1A2*1F (-163 A/C)69 
- Metabolism of caffeine ↓in 
CYP1A2*1F (-163 A/C)68 







strongest in CC82 





 Evidence linking OPEs to thyroid function  
Several OPE species have been shown to affect the endocrine system by exhibiting estrogenic83, 
anti-estrogenic83, or thyroid disruptive9-11, 84 effects. However, not all experimental studies observed 
toxicity and the directionality and the specific OPE species associated remain inconclusive. For example, 
TT3 antagonistic activities have been observed with TNBP and TDCIPP, but not with TPHP8. Elevated 
TPHP, in another study, altered gene expression and increased TT3 and TT484. The specific mechanism 
through which OPEs could disrupt thyroid function remains unclear, although one of the hypothesized 
pathways involves the receptor-ligand binding pathway8, 84.  
Critical review of previous epidemiologic literature – thyroid function disruption 
Five epidemiologic studies previously examined thyroid function in relation to OPE exposures in 
sub-fertile men9, 10, office workers11, rural community residents85, and electronic waste recycling 
workers86. Most studies suggested an association between OPE exposure and hyperthyroidism (i.e., 
suppressed TSH and elevated thyroxine or triiodothyronine)9-11, of which only one study included female 
participants11. In this previous study, urine and non-fasting blood samples were collected over three 
sampling rounds: winter 2010, summer 2010, and winter 2011. DPHP was assayed from the urine 
samples, and the blood samples were assayed to measure five biomarkers of thyroid function: total T3 
(TT3), free thyroxine, total T4 (TT4), thyroid stimulating hormone (TSH), and thyroid peroxidase 
antibody (TPOAb). The participants were non-pregnant office workers whose ages ranged from 24 to 66 
years, did not smoke, self-described themselves as healthy, and had no history of thyroid disease. The 
relationships between thyroid function biomarkers and OPE metabolites were modified by sex. Women 
with higher DPHP (upper tertile as cutoff: 2.65ng/mL) had elevated levels of TT4 (absolute mean 
difference: 0.91, 95% CI: 0.47, 1.36) and TT3 (relative mean difference: 1.05; 95% CI: 0.98, 1.13). 
However, near null and imprecise associations were observed for free thyroxine (relative mean difference: 
1.02; 95% CI: 0.95, 1.07) and TSH (relative mean difference: 0.91; 95% CI: 0.71, 1.68) in women. The 
authors reported no substantial change in results after excluding women who took oral contraceptives (4 
out of 25 women) or had elevated TPOAb levels (3 out of 25 women). Among men, elevated DPHP was 
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associated with higher concentrations of all thyroid function biomarkers. The other two previous studies 
that observed associations were in infertile men, with higher TT3 concentration in relation to elevated 
DPHP in urine (% change 3.9; 95% CI: -0.2, 1.8)9 and TPHP in dust (% change 2.0; 95% CI: -0.4, 6.9)10. 
Men with higher BDCIPP in urine also had substantially elevated TT3 (% change 6.6; 95% CI: 1.6, 12.8) 
and TSH (% change 40.3; 95% CI: 11.4, 77.1)9. 
Although all three epidemiologic studies that observed associations reported slightly higher TT3, 
the shortcomings of these studies limit our understanding of the impact of OPEs on thyroid disruption in 
pregnant women. All three previous studies were based on small sample size (n=28-51) with a wide age 
range (24-66 years) and mainly limited to DPHP. Only one study examined the relationship between 
BDCIPP and thyroid function, and reported contradictory results that are suggestive of hyperthyroidism 
(i.e., elevated TT3) and hypothyroidism (i.e., elevated TSH). Therefore, there is a need to re-examine the 
relationship between BDCIPP and thyroid function using comprehensive markers of thyroid function in a 
larger population. Further, the association in the context of correlated exposures remains unclear, where 
other flame retardants but no other plasticizers, have been considered11, 86. Most importantly, only a subset 
of previous studies included female participants11, 85, 86 and no information is available for pregnant 
women. Findings from the previous studies that included female participants11, 85, 86 are not directly 
generalizable to pregnant women since thyroid regulation is altered during pregnancy in response to 
increased metabolic needs in women13. For example, TT4 and thyroxine binding globulin increase while 
TSH decrease in the first trimester and remains different from the pre-pregnancy concentrations, although 
variable throughout pregnancy13. Given the pregnancy-induced changes in thyroid physiology, the 
relationship between OPE exposures and thyroid function among pregnant women may be different from 
those observed in non-pregnant populations.   
Maternal thyroid dysfunction and its relevance to fetal neurodevelopment 
The need to characterize the relationship between OPE exposures and thyroid function in 
pregnant women is highlighted by the impact of abnormal thyroid function on maternal and fetal health, 
including pregnancy loss12, 13, gestational diabetes14, low birth weight14, preterm delivery14, and 
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neurodevelopment15-18. One of the often-studied outcomes in relation to maternal thyroid function 
disruption is offspring neurodevelopment15-18. Thyroid hormones are critical to the developing fetus, 
given that triiodothyronine and thyroxine regulate gene expressions that are critical for central nervous 
system development, particularly neural migration, differentiation, myelination, and synaptogenesis87. 
However, the fetal thyroid gland does not mature until the end of the first trimester17. During the first half 
of pregnancy, a substantial amount of thyroxine is supplied to the fetus by the mother. Thyroxine is 
converted into the more biologically active triiodothyronine, once thyroxine reaches the fetal brain17. The 
fetus continues to rely partly on the maternal supply of thyroid hormones during the remainder of the 
pregnancy17.  
Given that maternal thyroid hormone supply during early pregnancy is critical to the development 
of the central nervous system of the fetus, maternal thyroid function disruption during early gestation may 
have detrimental effects on fetal brain development. Studies have linked maternal thyroid dysfunction 
during pregnancy to various aspects of neurodevelopment including poorer working memory, intelligence 
quotient (IQ), language development, brain volume, and hippocampal activation15. A clinical endpoint 
that has been often linked with thyroid function is ADHD, as summarized by a recent systematic review88. 
Studies observed a higher risk of ADHD with hypothyroidism, hypothyroxinemia, and hyperthyroidism 
during pregnancy, although the associations were inconsistent with regards to the specific type and 
markers of abnormal thyroid function. 
 Emerging evidence of OPEs as developmental neurotoxicants 
Given that thyroid function during pregnancy is a critical factor for the fetal development of 
central nervous system development, OPE exposures in utero may influence fetal brain development. In 
experimental settings, embryonic exposures to TDCIPP89 and TPHP90 have been associated with reduced 
neuronal gene expression, altered motor activities, and lower acetylcholinesterase activity. In the 
epidemiologic literature, the neurodevelopmental influence of OPE exposures was examined in three 
prospective studies22, 23, 51 and a cross-sectional study 21. The three prospective studies that examined the 
relationship between prenatal OPE exposures and neurodevelopmental symptoms in offspring were all 
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conducted in the US and used data from two pregnancy cohorts: Center for the Health Assessment of 
Mothers and Children of Salinas (CHAMACOS) Study in California or Pregnancy, Infection, and 
Nutrition Study (PIN) in North Carolina. Elevated concentrations of maternal urinary OPE metabolites 
during pregnancy were associated with poorer neurodevelopment in offspring, specifically worse 
cognitive performances23, 51 and more ADHD symptoms23 or behavioral problems22. OPE exposures 
measured in a wristband were also associated with more externalizing behaviors in 3-5-year-olds21; 
however, interpretation of these results is limited due to the cross-sectional study design. 
Details of the paper using Center for the Health Assessment of Mothers and 
Children of Salinas (CHAMACOS) Study 
CHAMACOS was used in the only study to assess the relationship between prenatal OPE 
exposure and ADHD symptoms in offspring23. A cohort of 601 pregnant women in a farmworker 
community in California was recruited from October 1999 – October 2000. The eligibility criteria 
included ≥18 years old, <20 weeks gestation, Spanish- or English-speaking, qualifying for low-income 
health insurance, and planning to deliver at a local public hospital. Each study participant provided a urine 
sample at her second prenatal study visit (26 gestational weeks), from which OPE metabolites including 
BDCIPP and DPHP were assayed. The offspring were followed up through age 7, at which their cognitive 
abilities were assessed with the Wechsler Intelligence Scale for Children 4th edition (WISC-IV). At age 
7, children’s behavior was assessed by interviewer-administered questionnaires to mothers and self-
administered questionnaires by the children’s teachers. ADHD-like behaviors (i.e., hyperactivity and 
inattention) were assessed with the Behavior Assessment System for Children 2 (BASC 2), and ADHD 
symptoms were assessed with Conners’ ADHD/diagnostic and statistical manual (DSM)-IV Scales. The 
Conners’ ADHD/DSM-IV Scales evaluate ADHD symptoms of inattention and hyperactivity/impulsivity 
based on one of the commonly used ADHD diagnostic criteria, DSM. Up to 310 children were analyzed 
to characterize the association between prenatal exposures to OPE metabolites and childhood 
neurodevelopment. Multivariable linear regression models were used, with backward covariate selection.  
A unit increase in log10 transformed BDCIPP was associated with more hyperactivity and 
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attention problems in all scales after adjustment for sex, age at assessment, maternal country of birth, 
home learning environment, prenatal OP pesticides, maternal depression, and maternal education, 
although imprecise. More attention problems were observed in relation to increased DPHP, however, the 
relationship between hyperactivity varied by rater (teacher vs. mother). In addition, investigators reported 
lower IQ (β:2.9; 95% confidence interval (CI): -6.3, 0.5) and working memory (β: 3.9; 95% CI: -7.3, -0.5) 
with a 1 unit increase in log-transformed DPHP; and more hyperactivity with isopropyl-phenyl phenyl 
phosphate (ip-ppp). The relationship between OPE metabolites and childhood neurodevelopment was not 
modified by sex.  
Details of papers using Pregnancy, Infection, and Nutrition Study (PIN)  
In the other two prospective studies that examined the relationship between prenatal exposure to 
OPE metabolites and neurodevelopment, the same pregnancy cohort, PIN, was used: 2006 pregnant 
women were recruited in North Carolina between 2001 and 200522, 51. The eligibility criteria were >16 
years old, ≤20 weeks gestation at enrollment, English-speaking, intending to continue care and deliver at 
UNC hospitals, carrying a singleton birth, and able to provide a phone number for contact. Each enrollee 
provided one urine sample during her prenatal follow-up visit (27 gestational weeks); from which four 
OPE metabolites including DPHP and BDCIPP were assayed. Cognitive development at 29-months was 
assessed via a mother-completed questionnaire on the child’s linguistic abilities (MacArthur-Bates 
communicative development inventories (MB-CDI); n=149). Cognitive and behavioral development at 36 
months was assessed via performance-based assessment administered by trained staff to children (Mullen 
scales of early learning (MSEL); n=227) and mother-completed questionnaire on child’s behavior (BASC 
2; n=199), respectively. Multivariable linear regression was conducted, adjusting for variables selected a 
priori based on their directed acyclic graphs (DAGs).  
In the paper that examined cognitive assessment scores as the outcome51, an interquartile range 
increase in ip-ppp was associated with worse cognitive assessment scores, although imprecise and near-
null associations were observed with DPHP and BDCIPP. When behavioral assessment scores were 
examined in the same pregnancy cohort22, elevated BDCIPP concentrations (i.e., highest and middle 
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tertile vs lowest tertile) were associated with more withdrawal and attention problems. Similarly, 
monotonically greater hyperactivity and attention problems were observed in higher tertiles of DPHP, 
although the estimates were not precise. There was limited evidence of effect measure modification by 
child sex, although authors reported a slightly higher impact on behavioral scores22 among girls. 
Critical review of previous epidemiologic literature – developmental neurotoxicity 
All three prospective studies observed adverse associations between maternal urinary OPE 
metabolite concentrations and offspring neurodevelopment, and did not observe strong evidence of 
modification by sex22, 23, 51. In the two studies that included ADHD-like behavior measured with the same 
neurodevelopment assessment tool (i.e., mother-reported BASC 222, 23), higher BDCIPP was associated 
with increased hyperactivity and attention problems. Although the magnitudes of association varied and 
the confidence intervals were wide, the directions of association were consistent. Moreover, in the only 
study that included multiple raters (mother and teacher) and tools related to ADHD (hyperactivity and 
inattention in BASC 2; and ADHD classification in Conners’ ADHD/DSM-IV Scales), similar adverse 
associations were observed across rater and assessment tools23. Higher DPHP in prenatal urine was also 
associated with increased mother-reported attention problems measured with BASC 222, 23. Although 
similar associations were reported in teacher-reported measures, the direction of association was 
inconsistent when compared to other mother-reported measures23. Further inconsistencies were reported 
between DPHP and hyperactivity23, 51. When the two studies examining cognitive test scores were 
compared, the directionality or magnitude of the associations with DPHP or BDCIPP did not show a 
consistent trend.  
Such heterogeneity in results could be due to the differences in the neurodevelopment assessment 
tools, administration of assessment (direct child assessment vs parent/teacher report), and child’s age at 
examination (7 years vs 29~36 months). Additional sources of heterogeneity include differences in the 
study populations: exposures, occupation, race/ethnicity, and socioeconomic status. Castorina and 
colleagues studied pregnant women in a Mexican-American farmworker community (CHAMACOS study 
in California) who are planning to give birth at a local public hospital, whereas Doherty and colleagues 
 
16 
studied pregnant women (PIN study in North Carolina) seeking services from UNC hospital. Since 
farmworker community members are likely exposed to higher concentrations of pesticides and other 
mixtures of environmental pollutants, their co-exposure pattern of environmental exposures may be more 
complex than that in an urban environment such as the PIN study. The exposure concentrations also vary 
in the two populations, with the median concentrations of DPHP slightly higher in CHAMACOS but 
BDCIPP much higher in PIN (Table 1). If the dose-response relationship is non-linear, such differences in 
exposure levels may have contributed to the heterogeneous results. Another point to note is that the 
majority of participants in CHAMACOS were Mexican-American families who qualified for low-income 
health insurance, whereas the study participants in PIN were predominantly white and well-educated. 
Socially deprived populations may be more susceptible to the adverse effects of environmental pollution 
due to their relative disadvantage (e.g., poor nutrition and access to health care) and psychosocial stress91, 
92. Therefore, further research using another population will contribute to a better understanding of the 
relationship between prenatal exposure to OPEs and neurodevelopment.  
These epidemiologic studies laid the groundwork connecting OPE exposures to 
neurodevelopment measured with different assessments. Research using a clinically validated endpoint of 
ADHD will further our etiologic understanding of prenatal OPE exposure. The collective evidence of 
OPEs’ potential for neurotoxicity21, 23, 51, thyroid function disruption9-11, 84, and the critical role of maternal 
thyroid hormone supply during early pregnancy17, 87 points to prenatal OPE exposure as a potential risk 
factor for ADHD through maternal thyroid function disruption. Maternal OPE exposures during 
pregnancy may additionally disrupt thyroid function in the fetus by crossing the placenta, since several 
OPE metabolites have been identified in human chorionic villi93 and placenta94. Maternal-fetal transfer of 
OPEs89, 90 opens another possibility of OPEs’ direct effects on neurotransmitters and neurogenesis, given 
that the metabolic enzymes are not fully functional in the fetus (immature metabolic pathways). 
Therefore, there are multiple pathways through which prenatal exposure to OPEs could plausibly affect 















Table 3 Summary of epidemiologic studies examining OPE metabolites and neurodevelopment in children 
 Castorina et al.,23 Doherty et al.,22  Doherty et al.,51 Lipscomb et al.,21 
Study characteristics 
Approach (N) Cohort (310) Cohort (227) Cohort (199) Cross-sectional (72) 
Year, region 1999 – 2000, CA, US 2001-2005, NC, US 2001-2005, NC, US 2012-2013, OR, US 
OPE or metabolites 
Species DPHP, BDCIPP, ip-ppp DPHP, BDCIPP, ip-ppp, BCIPHIPP ∑TPHP, TDCIPP, TCPP, TCEP 
Medium Urine (specific gravity adjusted) Urine (specific gravity adjusted) Wristband 
Exposure window 26 gestational weeks 27 gestational weeks 7 days at age 3-5 
%> LOD 79, 78, 72 84, 93, 99, 98 97, 96, 92, 89 





related to ADHD 
underlined) 





















Activities of daily living 
Adaptability 
Communication 




















Child age 7 year 36 months 29 - 36 months 3-5 years 
Methods (all studies used linear regression) 
Covariates Maternal education, country of 
birth, depression, pesticide, 
intelligence; child sex, age, 
language; household poverty; 
home learning environment 
Maternal age, race, BMI, 
education, depression; 
child sex; poverty index; 
home environment score 
Maternal age, education, 
race, BMI; child sex; 
poverty index 
Parent education, income; 
adverse experience; child sex, 
age; home learning 
environment 
Model selection Backward selection (p<0. 2) Based on DAG Based on DAG Not specified 
Sensitivity  
analyses 
Adjusted DDT, DDE, PBDE 












Table 3 (Continued) 
 Castorina et al. , 23 Doherty et al. , 22 Doherty et al. , 51 Lipscomb 21 







 Hyperactivity inconsistent 
Mother BASC: -0.6 (-2.5, 1.3) 
Mother CADS: -0.8 (-2.7, 1.1) 
Teacher BASC: 1.4 (-1.2, 3.9) 
Teacher CADS: 1.0 (-1.8, 3.8) 
 More attention problems 
Mother BASC: 0.8 (-1.7, 3.2) 
Mother CADS: -0.9 (-2.6, 0.8) 
Teacher BASC: 1.0 (-0.9, 3.0) 
Teacher CADS: 1.0 (-1.3, 3.3) 
 Poorer working memory: 
-3.9 (-7.3, -0.5)  
 Worse verbal conception: 
-1.8 (-5.0, 1.4) 
 Monotonic hyperactivity ↑ 
t1 vs t2: 0.18 (-2.7, 3.0) 
t1 vs t3: 1.14 (-1.7, 4.0) 
 
 
 Monotonic attention problem ↑ 
t1 vs t2: 0.31(-2.52, 3.14) 
t1 vs t3: 2.39(-0.44, 5.22) 
 
 
 Monotonic externalizing ↑ 
t1 vs t2: 0.26 (-2.40, 2.92) 
t1 vs t3: 1.44 (-1.22, 4.09) 
 Monotonic behavior symptom ↑ 
t1 vs t2: 1.07 (-1.61, 3.75) 
t1 vs t3: 1.98 (-0.70, 4.66) 
 Cognitive scores 
inconsistent 
Fine motor: 
-0.50 (−2.35, 1.35) 
Visual reception:  
0.49 (−1.49, 2.47)  
Receptive language:  
0.12 (−1.39, 1.64) 
Expressive language: 
-0.06 (-1.48, 1.37) 
Vocabulary:  
















 More hyperactivity  
Mother BASC: 0.9 (-0.3, 2.1) 
Mother CADS: 0.8 (-0.4, 2.0) 
Teacher BASC: 0.5 (-1.1, 2.1) 
Teacher CADS: 0.9 (-0.8, 2.6) 
 More attention problems 
Mother BASC: 0.5 (-1.0, 2.1) 
Mother CADS: 0.4 (-0.7, 1.5) 
Teacher BASC: 1.1 (-0.1, 2.3) 
Teacher CADS: 0.5 (-0.9, 1.8) 
 Monotonic hyperactivity ↑ 
t1 vs t2: 1.60 (-1.16, 4.37) 
t1 vs t3: 2.32 (-0.49, 5.12) 
 
 
 More attention problem ↑ 
t1 vs t2: 2.86 (0.11, 5.61) 
t1 vs t3: 2.36 (-0.43, 5.16) 
 
 
 Monotonic externalizing↑ 
t1 vs t2: 0.34 (-2.33, 2.91) 
t1 vs t3: 2.49 (-0.12, 5.10) 
 Monotonic behavior symptom ↑ 
t1 vs t2: 1.87 (-0.72, 4.47) 
t1 vs t3: 3.03 (0.40, 5.67) 
 Worse cognitive scores 
Fine motor: 
-0.10 (−2.41, 2.22) 
Visual reception:  
−0.10 (−2.61, 2.41)  
Receptive language:  
−0.61 (−2.52, 1.31) 
Expressive language: 
0.2 (-1.58, 1.99) 
Vocabulary:  






2.2. Attention deficit hyperactivity disorder (ADHD) 
 Prevalence and impact of childhood ADHD 
ADHD, as characterized by hyperactivity, impulsivity, and inattentiveness24, is the most 
commonly diagnosed psychiatric disorder in children. Although ADHD has been most extensively 
studied in the US, with 6.1 million children aged 2-17 ever diagnosed with ADHD in 2016 (prevalence: 
9.4%)95, children are also commonly diagnosed with ADHD around the globe. The prevalence of ADHD 
ranges from 3% to 19%, with the worldwide pooled prevalence of 5%96 and the prevalence in Norway 
estimated at 3.8% in 12-year-olds97. Country-related variability in ADHD prevalence can be, in part, due 
to the use of different ADHD diagnostic criteria.  
Two commonly used diagnostic criteria are hyperkinetic disorder defined in the international 
classification of the disease 10th edition (ICD-10) and DSM-IV98. The ICD-10 classification is commonly 
used in some European countries99, 100, and captures a narrow category of ADHD cases. All three 
symptoms of inattention, impulsiveness, and hyperactivity must be present in a pervasive manner (evident 
in two independent situations), excluding cases with anxiety disorder, mood disorder, schizophrenia, or 
other pervasive developmental disorders. In contrast, DSM-IV criteria are used in America101 and capture 
a broader category of ADHD cases. One or more of the three symptoms must be present in two or more 
situations, allowing ADHD diagnosis in patients with comorbid conditions. Under DSM-IV, ADHD cases 
can be categorized into three subtypes: predominantly inattentive, predominantly hyperactive-impulsive, 
and combined type102. The combined type of ADHD in DSM-IV requires all three symptoms of 
inattention, impulsiveness, and hyperactivity to be present. Therefore, the combined type of ADHD in 
DSM-IV is similar to the definition of hyperkinetic disorder in ICD-10, however, ADHD cases with 
comorbid psychiatric disorders are also captured in DSN-IV. This dissertation uses the ADHD diagnostic 
criteria based on ICD-10, which is reported mandatorily in the Norwegian Patient Registry (NPR).  
Children with ADHD suffer from short- and long-term health consequences. Children with 
ADHD are more likely to have comorbid psychiatric disorders including learning disabilities and mental 
disorders103, show poor academic performance, and are at a higher risk of injuries requiring medical 
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attention104. In addition, childhood and adolescent ADHD is costly since the treatment entails high annual 
excess cost, reaching € 2,546 million in Europe105 and $31.6 billion in the US in 2000106. The impact of 
childhood ADHD persists into adulthood since ADHD is not a transient disorder: more than 30% of adult 
ADHD had a history of ADHD during childhood107. Studies have shown that adults with a history of 
ADHD were more likely to engage in risky behaviors such as substance abuse108, were more likely to be 
in traffic accidents109, 110, and receive criminal convictions111.  
 Etiology and risk factors of ADHD 
Despite the public health importance of ADHD, the risk factors for ADHD are not well 
characterized apart from heritability112. Heritability in familial studies can be calculated with the 
difference in ADHD variability among dizygotic and monozygotic twins divided by the ADHD 
variability among monozygotic twins. Previous studies reported an average heritability of 0.77113, which 
is often interpreted as 77% of the ADHD variability explained by genetic variability in that population. 
High heritability estimated from family-based studies, however, include gene-environment interactions 
and cannot be attributed to a single genetic variant. A few genes such as dopamine transporter genes (e.g., 
DAT1114) and dopamine receptor genes (e.g., DRD4115) have been linked to ADHD, however, results 
from replication studies remain inconclusive116, 117, with the pooled odds ratios from a meta-analysis 
ranging from 1.34 to 1.68 118. Rather than a single genetic variant explaining the etiology of ADHD, it has 
been hypothesized that many rare genetic variants collectively contribute to the etiology of ADHD. 
Individuals with such rare genetic variants may be genetically predisposed to ADHD; however, they may 
not develop ADHD until they are exposed to environmental triggers. A well-characterized example of 
such gene-environment interaction is phenylketonuria119. Phenylketonuria is caused by an autosomal 
recessive inborn error of phenylalanine metabolism, however, manifests only under exposure to diets 
containing phenylalanine119. As the variability in ADHD incidence cannot be fully explained by genetic 
factors alone, there is a need to identify modifiable risk factors103, 120.  
To date, multiple non-genetic risk factors have been hypothesized to increase the risk of ADHD. 
Excessive or deprived thyroid hormone during pregnancy has been linked to ADHD or ADHD 
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symptoms16, 88. Additional maternal risk factors during pregnancy include medication use including 
acetaminophen121, 122, stress123-125, cigarette smoking123, 126, 127, and alcohol consumption127, 128. Higher odds 
of ADHD have also been observed in relation to adverse birth outcomes such as preterm delivery129 and 
low birth weight129, 130. Being a middle child or living with the biological parents reduced the odds of 
ADHD131, and additional parental factors have been linked to ADHD: maternal age at birth132, maternal 
BMI133, marital status134, parental education135, and socioeconomic status129, 130, 136, 137. Higher prevalence 
of ADHD or neuropsychiatric disorders has been observed in boys138, 139, children born in winter or spring 
months140, and children with higher BMI141, although the causality and the biological underpinning 
remains unclear. In recent years, an increasing number of studies report elevated ADHD with increased 
exposures to environmental contaminants such as lead134, mercury125, polychlorinated biphenyls142, and 







CHAPTER 3. INNOVATIONS 
 
There are multiple innovative aspects of this dissertation, using secondary data from the MoBa 
study. This is the first investigation to evaluate prenatal exposure to OPEs as a risk factor for clinically 
confirmed ADHD (Aim 2), and to characterize a plausible mechanism by characterizing the relationship 
between exposure to OPEs and thyroid function in pregnant women (Aim 1). Additional innovative 
aspects of this proposal include a) exploration of modification by SNPs potentially involved in OPE 
metabolism; b) comprehensive assessment of thyroid function in pregnant women, which may mediate 
associations between OPE exposures and neurodevelopment; and c) application of mixtures perspective. 
3.1.  Investigation of modification by SNPs in PON1 and CYP1A2 
Enzymes in human serum49 and liver55, 60 are involved in the phase-I and phase-II metabolism of 
OPEs, although the specific enzymes have not been identified. Candidate enzymes include CYP1A2 and 
PON1, which are human enzymes commonly involved in the metabolism of multiple xenobiotics55, 58, 144 
including organophosphate pesticides71, 145. The concentrations and activity of CYP1A2 and PON1 
enzymes are known to be affected by functional polymorphisms. Individuals with specific SNPs may 
metabolize OPEs at a slower rate, potentially increasing their vulnerability to any adverse effects of OPE 
exposures. Modification by SNPs has been studied in the context of organophosphate pesticides75, 146, 
however, no study to date has assessed their role in OPE exposure.  
This dissertation took advantage of the MoBa genotype data, in order to examine modification by 
measured SNPs in CYP1A2 and PON1 among mothers. Selected SNPs with established functional 
polymorphisms in PON1 (i.e., L55M and Q192R) and CYP1A2 (i.e., -1545C/T) were investigated. 
Modification by any of the candidate SNPs identified in the current dissertation can help inform future 
experimental studies to delineate the relevant metabolic pathways of OPEs. Additionally, the results will 
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contribute to identifying populations that may be more vulnerable to any potential adverse effects of 
OPEs. 
3.2.  Investigation of maternal thyroid function during pregnancy using comprehensive 
biomarkers 
There have been no previous studies on the relationship between OPE exposure and thyroid 
function among pregnant women. Only a subset of previous studies examined the relationship between 
DPHP and thyroid function among females11, 85, 86; however, these studies excluded pregnant women. 
Pregnancy greatly influences thyroid function in women (e.g., decreased TSH and increased thyroid 
hormones13). Maternal thyroid function is a critical determinant of fetal neurodevelopment17, 87, 147, and 
has been associated with offspring ADHD88. Therefore, there is a need to characterize the relationship 
between exposure to OPEs and thyroid function in pregnant women. This dissertation addresses the gap 
in knowledge by leveraging a comprehensive assessment of maternal prenatal thyroid function in order to 
fully characterize the relationship between urinary metabolites of four OPEs and thyroid function (Aim 
1).  
3.3. Consideration of correlated nature of exposure to environmental stressors 
Humans are often simultaneously exposed to multiple plasticizers and flame retardants1. A group 
of commonly used plasticizers, phthalates, has been linked to ADHD25, ADHD-like behaviors148-168, and 
thyroid function169-171. Given that phthalates may be an independent risk factor for ADHD and thyroid 
dysfunction, there is a need to consider such correlated nature of exposure. Characterizing the 
independent associations of individual exposures could be helpful in prioritizing exposures for 
population-wide policies. On the other hand, quantifying the impact of jointly increasing exposure to a 
mixture of correlated exposures could be helpful to conceptualize the impact of behavioral interventions 
that are targeted to joint exposure reductions, such as cleaning more often. Therefore, this dissertation 
took advantage of the existing phthalates exposure data available in the MoBa study and considered the 
co-distributions of OPE and phthalate metabolites to answer two distinct questions that can be asked in 




CHAPTER 4. METHODS 
 
4.1. Overview of Study Design 
In order to evaluate exposure to OPE during pregnancy as risk factors for offspring ADHD and 
the potential mechanism through maternal thyroid function disruption, a case-cohort study was nested 
within the MoBa (Figure 3). In Aim 1, the study population was restricted to pregnant women with 
normal thyroid function in the sub-cohort. A cross-sectional investigation was conducted to characterize 
the relationship between urinary OPE metabolites and biomarkers of thyroid function, considering the 
confounding by co-occurring phthalate and OPE metabolites. In Aim 2, pregnancy exposure to the four 
OPE metabolites were evaluated as risk factors for ADHD in offspring, and further quantified the impact 
of joint reduction in correlated exposures. Modification by SNPs that regulate candidate enzymes for OPE 
metabolism was assessed and the impact of jointly increasing exposure to OPE and phthalate mixture was 
quantified. 
 




4.2.  Study Population 
 Preliminary study: Norwegian Mother, Father and Child Cohort (MoBa) 
All births occurring in Norway from 1999 through 2008 were targeted for enrollment in MoBa172. 
Pregnant women and their partners were recruited from 50 participating hospitals, resulting in over 
114,000 children from almost 113,000 pregnancies. Throughout the study period, roughly 41% of all 
births participated in MoBa173. The MoBa participants, when compared to all women giving birth in 
Norway, consisted of a lower proportion of mothers aged less than 25, living alone, and multiparous174. 
An invitation was sent to women prior to their routine prenatal ultrasound, which up to 98% of 
pregnant women in Norway have before her 20 gestational weeks175. During the ultrasound visit, the 
women and their partners were asked for participation and provided urine and blood samples upon 
providing written consent. Collected bio-samples were shipped to the Biobank in Oslo overnight 
unrefrigerated176, where they were processed. The bio-sample collection and quality control procedures 
had been published in detail previously, with pilot studies ensuring the suitability of the stored 
specimens177, 178. Additionally, mothers completed questionnaires during and after pregnancy, and their 
pregnancy outcome data were obtained from the Medical Birth Registry of Norway. 
During the ultrasound appointment at 17-18 gestational weeks’ gestation, each mother provided 
an 8ml urine sample and blood samples (Table 4179). The collected urine samples were transferred to urine 
transport tubes with Chlorhexidine to prevent bacterial growth during preservation. The biosamples were 
shipped unrefrigerated to a central processing lab in Oslo (Biobank; ISO-certified). To prevent sample 
identity mix-up at the Biobank, each biosample was assigned a unique Biobank ID and linked to the 
participants’ MoBa ID. Details of participants, sample collection, and storage were recorded using the 
Laboratory Information Management System176. Urine samples were aliquoted into six 930ul Matrix 
plates and stored at -80°C. DNA was extracted from blood samples using the FlexiGene kit (Qiagen, 
Hilden, Germany) and stored at -20°C. The remainder of the blood samples were separated into plasma 
and serum, where plasma samples were aliquoted into three 930ul Matrix plates and stored at -80°C. The 
majority of samples were received, processed, and stored within 24 to 48 hours after collection. 
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The stored bio-samples were shipped to the Norwegian Institute of Public Health for the assay of 
urinary OPE and phthalate metabolites, and genotyping of select SNPs. The plasma samples were shipped 
to ARUP Laboratories (Salt Lake City, Utah, USA), frozen on dry ice, for the assay of thyroid function 
biomarkers. 
Table 4 Biosamples from MoBa used in this dissertation: collection, processing, and storage 
Type Vial Processing Storage Assay 
Urine Collected in an 8ml urine cup;  
transferred to urine transport  
tubes with chlorhexidine 
Aliquoted into six 930ul 
Matrix plates 
-80°C  OPE metabolites 
Phthalate metabolites 
Blood 2 7-ml EDTA tubes 
1 7-ml anticoagulant tube 
1 plastic 3-ml EDTA tube 
Plasma separated and 
aliquoted into three 
930ul Matrix plates 
-80°C  Thyroid function 
biomarkers 
DNA extracted -20°C Genotyping for 
maternal PON1 and 
CYP1A2  
 
 Aim 1: Cross-sectional study of pregnant women  
The sub-cohort pregnancies were used to cross-sectionally investigate the relationship between 
four urinary OPE metabolites and maternal thyroid function during pregnancy (Figure 3; “Sub-cohort”). 
Prior to analysis, the study population was further restricted to pregnancies with normal functioning 
maternal thyroid glands, i.e., euthyroid population, since the measured thyroid in the non-euthyroid 
population may have been affected by medical interventions. The euthyroid population was constructed 
by excluding from the sub-cohort, 1) self-reported pre-existing thyroid disease diagnosis (N=25); 2) self-
reported taking thyroid medication (N=15); or 3) had evidence of current thyroid dysfunction as 
determined by measured biomarkers of TSH, TPOAb, and FT4i concentrations (N=15; TSH<0.19 and/or 
FT4i>14.03; FT4i<7.73; TSH>4.06 and TPOAb>9). 
 Aim 2: Case-cohort study  
A case-cohort study was nested within MoBa to assess maternal exposure to OPE during 
pregnancy as a risk factor for offspring ADHD (Figure 3; “Sample of ADHD cases not already in sub-
cohort” and ”Sub-cohort”). The eligibility criteria were identical to that of the MoBa Preschool ADHD 
Substudy, in order to utilize the sub-cohort population that had been defined previously25. This includes 
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singleton births without Down’s syndrome or cerebral palsy that were born between 2003 and 2008, 
donated a urine sample during pregnancy, completed the standard MoBa questionnaire when the child 
was 36 months old, and resided within proximity to Oslo, Norway25.  
Among the eligible population, cases and sub-cohort were selected using a case-base sampling 
approach180. In a case-cohort study, the standard estimation of odds ratios can be interpreted as risk ratios 
(RR) if the sub-cohort is selected at baseline irrespective of their case status and the sub-cohort comprised 
only the cases outside the sub-cohort181.  
4.3. Assessment of Organophosphate Esters Exposure 
Four OPE metabolites (i.e., DNBP, DPHP, BDCIPP, and BBOEP) were assayed from maternal 
urine samples collected at 17-18 gestational weeks.  
OPE metabolites were assayed in batches that included randomly assigned cases (n=19 per 
batch), non-cases (n=34~36 per batch), and two types of quality control (QC) urine samples: in-house lab 
samples and laboratory-blinded pooled urine samples. The laboratory-blinded pooled urine samples were 
created from a single homogenized pool of urine samples and are reflective of the typical OPE metabolite 
concentrations expected in the study population. A total of 10 to 11 pooled urine QC samples were 
included in each analytic batch. A total of 8 lab QC samples were included in each analytic batch to 
assess the assay precision at the typical concentrations at which the assay was developed: 3 spiked at 
5µg/L, 3 spiked at 15µg/L, and 2 blank samples. 
Analysts blinded to QC sample and ADHD status measured OPE metabolites in batches, using 
ultra performance liquid chromatography (UPLC) coupled with quadrupole-time-of-flight (QTOF) by a 
modified method published previously182. The modification was applied in the sample preparation 
procedure and was adapted from an earlier published method183. In brief, labeled internal standards, 300 
µL of water, and 40 µL of formic acid were added to 300 µL of the urine sample. The OPE metabolites 
were extracted using Strata-X-AW 96-well plates (Phenomenex, U.S.A.), which were conditioned first 
with 0.5 mL of MeOH and subsequently with 0.5 mL of H2O, both containing 1% formic acid. Samples 
were loaded, eluted by gravity, and washed with 0.5 mL of MeOH to remove neutral interferences. The 
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OPE metabolites were then eluted with 0.5 mL of acetone containing 5% triethylamine. Fifty microliters 
of water were added and the samples were evaporated with a gentle stream of nitrogen (10 L/hour) for 1 
hour. Ten microliters were injected into the UPLC system as described elsewhere182. UPLC was 
performed using Acquity® C18 BEH c1olumn (50mm× 2.1 mm× 1.7 μm) from Waters Corp. (Milford, 
MA, U.S.A.). The metabolites were identified and quantified with tandem mass spectrometry using a 
Xevo® G2-S QTOF from Waters Corp. (Milford, MA, U.S.A.). 
4.4.  Outcome Assessment 
 Outcome assessment for Aim 1 – maternal thyroid function 
Six biomarkers for maternal thyroid function were examined, namely TSH, FT4i, TT4, FT3i, TT3 
and TT3:TT4 ratio. TPOAb was served as an additional covariate to identify the euthyroid population. 
TPOAb, TSH, TT4, and TT3 in plasma samples were estimated using electrochemiluminescent 
immunoassays on the Roche Cobas e602 analyzer (Salt Lake City, Utah, USA)25. The concentrations of 
FT4i and FT3i were calculated using the measured TT4, TT3, and T3 uptake (equation 1). Indirect 
assessment of FT4i and FT3i is preferred over direct measurement during pregnancy, since direct 
measurement of FT4i and FT3i may not accurately characterize the true levels due to high variability in 
maternal thyroid-binding globulin levels during pregnancy13.  
𝐹𝑇4𝑖(𝑜𝑟 𝐹𝑇3𝑖) =  
𝑇𝑇4(𝑜𝑟 𝑇𝑇3) × (𝑇3 𝑢𝑝𝑡𝑎𝑘𝑒, %)
𝑀𝑒𝑑𝑖𝑎𝑛 𝑜𝑓 𝑙𝑜𝑤 𝑣𝑎𝑙𝑢𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑜𝑓 𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑜𝑟𝑦 𝑇3 𝑢𝑝𝑡𝑎𝑘𝑒
  
Equation 1. Computation of free thyroxine or free triiodothyronine indes 
The approach to estimating thyroid function biomarkers in MoBa has been validated in a previous 
study in North Carolina184. In the validation study, plasma concentrations of FT4i were highly correlated 
with the gold standard of equilibrium dialysis using serum (Spearman’s Rho: 0.97; 95% CI: 0.84, 1.00). 
The plasma concentrations of TPOAb, TSH, TT4, and TT3 were not affected substantially by the time left 
in ambient temperature (0, 24, or 48 hours) and the number of freeze-thaw cycles (1 or 2); although TT3 




 Outcome assessment for Aim 2 – ADHD 
The sub-cohort (n=555) was sampled at baseline from MoBa enrollees eligible for the ADHD 
Substudy, whose birth years were frequency-matched to the preschool ADHD cases evaluated at 3.5 
years. This included two ADHD cases that had been identified through data linkage with NPR. 
All eligible MoBa enrollees were linked to NPR based on their 11-digit personal identification 
number in Norway. The NPR data linkage was conducted in 2014, which allowed the identification of 
children with disease registrations during the period 2008 through 2014. The NPR data includes 
registration of hyperkinetic disorders, which is mandatorily reported in Norway. Individuals first 
diagnosed with or continuing to seek care/treatment for hyperkinetic disorders are registered into NPR. 
Hyperkinetic disorder is based on ICD-10 codes for mental and behavioral disorders, specifically F90, 
F90.0, F90.1, F90.8, or F90.9185. This classification captures a narrow group of ADHD cases, where all 
three symptoms of inattention, hyperactivity, and impulsivity are present, and is similar to the combined 
type of ADHD based on DSM-IV. To exclude erroneous or false diagnoses, ADHD cases were defined as 
having at least two registrations of hyperkinetic disorder from 2008 through 2013. From all identified 
ADHD cases born in 2004-2008, 266 were randomly sampled. An additional 32 ADHD cases were 
randomly sampled from births that occurred in 2003. Of the 298 ADHD cases identified from the NPR 
registry, 2 were already in the sub-cohort and therefore excluded from the ADHD case group. 
4.5. Covariate assessment 
 Urinary phthalate concentrations at 17 weeks gestation 
Quality-controlled data on 12 phthalate metabolites177, 178 were utilized: monoethyl phthalate 
(MEP); mono-iso-butyl phthalate (MiBP); mono-n-butyl phthalate (MnBP); monobenzyl phthalate 
(MBzP); mono-2-ethylhexyl phthalate (MEHP), mono-2-ethyl-5-hydroxyhexyl phthalate (MEHHP), 
mono-2-ethyl-5-oxoyhexyl phthalate (MEOHP), mono-2-ethyl-5-carboxypentyl phthalate (MECPP), and 
mono-2-methylcarboxyhexyl phthalate (MMCHP), metabolites of DEHP; and mono-4-methyl-7-
hydroxyoctyl phthalate (OH-MiNP), mono-4-methyl-7oxooctyl phthalate (oxo-MiNP), and mono-4-
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methyl-7-carboxyheptyl phthalate (cx-MiNP), metabolites of di-iso-nonyl phthalate (DiNP) 
 Genotype data 
Given that OPE metabolism may be modified by enzymatic activities of PON1 and CYP1A2, 
modification by select SNPs with well-established functional polymorphisms were assessed using 
maternal DNA from blood samples collected at enrollment. Maternal blood samples were collected in 
EDTA tubes at approximately 17 weeks’ gestation. Plasma was separated before shipment overnight to 
the MoBa Biobank. Immediately after birth, an umbilical cord blood sample was collected, shipped to the 
biobank, and plasma separated upon arrival. All samples were stored at -80°C until analysis179. Maternal 
and fetal DNA was extracted from blood samples using the FlexiGene kit (Qiagen, Hilden, Germany) and 
stored at -20°C. For genotyping, three SNPs with established functional polymorphisms on candidate 
enzymes that may metabolize OPEs were selected: PON1 Q192R, PON1 L55M, and CYP1A2 -1545C/T. 
Genotyping was conducted at the Norwegian University of Life Sciences (NMBU) using the Sequenom 
MassARRAY IPLEX® platform186.   
 MoBa standard questionnaire data 
Covariate data were obtained from the MoBa questionnaire that was mailed to participants at 15 
weeks’ gestation, from the food frequency questionnaire that mothers completed at ~22 weeks’ gestation, 
and from data linkage with the Medical Birth Registry of Norway (MBRN). From the 15 weeks’ 
questionnaire, maternal characteristics reported by mothers were obtained: preexisting thyroid disease, 
thyroid medication, education, depression before or during pregnancy, smoking during the first or second 
trimester of pregnancy, and alcohol intake during pregnancy.  
Maternal iodine and selenium intake during pregnancy were estimated from a food frequency 
questionnaire that mothers completed at 22 weeks’ gestation187. Briefly, pregnant women responded to a 
semi-quantitative questionnaire that is intended to characterize diet during the first four months of 
pregnancy via 255 food items and additional dietary supplements. The dietary iodine and selenium 
intakes calculated from the food frequency questionnaire (g/day) were moderately correlated with that 
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from four-day weighed food diary (?̂? for iodine: 0.46; ?̂? for selenium: 0.28) or 24-hour urine (?̂? for 
iodine: 0.38)187, 188. 
 Data linkage to Medical Birth Registry of Norway 
Maternal age at delivery, preexisting thyroid disease, and parity were obtained. 
Table 5 Covariates for the assessment of specific aims: collection and relationship with OPEs and outcome 
 Source Units Aim 1 Aim 2 
OPE metabolites Urine ug/mL E E 





Offspring ADHD  Patient registry Yes (2 or more)/No  - O 
Maternal Characteristics     
ADHD Self-report Adult Self-Report Scale scores C C 
Education Self-report <college, college, >college, other C C 
Depression  Self-report Yes/No . C 
Fish consumption Self-report g/day C C 
Nulliparity Self-report Yes/No . C 
Prepregnancy BMI Self-report Kg/m2 C C 
Phthalates (17-18 gestation) Urine ug/L C C 
Age at delivery Self-report Years C C 
Marital status Self-report Married, cohabiting, single . C 
Alcohol (1st/2nd trimester) Self-report Yes/No . C 
Smoking Self-report Yes/No . C 
Iodine Urine ug/L C . 
Selenium Self-report ug/day C . 




Offspring Characteristics     
Birth year Birth record 2003-2004; 2005; 2006; 2007-2008 C C 
Sex Birth record Girl/boy . M 
OPE Characteristics     
Collection month Lab January-December C C 
Analytic batch Lab N/A E E 
Specific gravity Lab N/A (unitless) E E 
Abbreviations: 






4.6.  Analytic approach 
 Data handling of OPEs 
Prior to utilizing the concentrations of urinary OPE metabolites, laboratory errors in estimating 
OPE metabolite concentrations were examined using the QC samples189. The concentrations below LOD 
were imputed using the approach most appropriate for each aim, as described in the following sections. 
Urinary dilution was then considered using specific gravity by normalizing the individual’s specific 
gravity minus 1 to the geometric mean of all study participants minus 1 (equation 2).  
𝑃𝑖𝑗
∗ = 𝑃𝑖𝑗 ×
𝑆𝐺𝐺𝑀−1
𝑆𝐺𝑗−1
   
Equation 2. Specific gravity correction 
𝑃𝑖𝑗
∗ : Specific gravity-corrected concentration of ith OPE metabolite in jth person’s urine 
𝑃𝑖𝑗: Raw concentration of i
th OPE metabolite in jth person’s urine 
𝑆𝐺𝐺𝑀: Geometric mean of specific gravity in the total study population 
𝑆𝐺𝑗: Specific gravity of j
th person.  
 Approach for Aim 1 
A DAG reflective of the relationship between urinary OPE metabolite and plasma thyroid 
function biomarker was generated and the corresponding minimally sufficient adjustment sets were 
identified (Figure 4). In this cross-sectional investigation of euthyroid pregnant women, descriptive 
statistics and distributions all covariates were generated and examined.  
The relationship between individual OPE metabolite and thyroid function biomarkers, 
considering confounding by other OPE and phthalate metabolites, were characterized using general linear 
regression (GLM) and Bayesian kernel machine regression (BKMR). Since the analysis of multiply 
imputed datasets was not supported in BKMR at the time of analysis and only 3% of the participants had 
missing covariate information, a complete case analysis was conducted. Further, OPE metabolites were 
restricted to the highly detected OPE metabolites (>80%), whose concentrations below the LOD was 
substituted with LOD/√2. Sensitivity analyses were conducted to examine the robustness of findings with 












 Approach for Aim 2 
A DAG reflective of the relationship between prenatal OPE exposure and ADHD development 
was developed and the corresponding minimally sufficient adjustment sets were identified (Figure 5). In 
this case-cohort investigation, the descriptive statistics and distributions of all covariates were generated 
by case/sub-cohort status. Due to missing covariates and exposure concentrations below the limit of 
detection, multiple imputation was conducted. 
In a case-cohort study, the standard estimation of odds ratios can be interpreted as RRs if the sub-
cohort is selected at baseline irrespective of their case status. Further, restricting the case group only to 
cases who are not already sampled into the sub-cohort allows the estimation of variance using the 
standard formula for odds ratios181.RRs were estimated in each dataset using logistic regression and 
pooled across using Rubin’s rule. All models were adjusted for confounders, including co-exposure to 
phthalates. The functional forms of OPE metabolites were compared using continuous, quartile-based, 
and binary exposure classifications. 
For the OPE metabolite that exerted both thyroid disruptive and neurotoxic associations, 
mediation analysis was conducted to decompose the total effect of the OPE metabolite on ADHD into a 
natural direct effect and a natural indirect effect through maternal thyroid function during pregnancy, 
using a previously published method190, 191. Effect measure modification by SNPs of relevant 
metabolizing enzymes and child sex was explored using an augmented term approach. The impact of 
exposure to mixtures of frequently detected OPE metabolites and phthalates were estimated using 
quantile based g-computation. Sensitivity analyses were conducted with alternative definitions of 
exposure mixture in quantile based g-computation and an alternative genotype modeling approach in the 




Figure 5 Directed acyclic graph of the relationship between pregnancy exposure to organophosphate esters (OPEs) and offspring attention deficit 








CHAPTER 5. PREGNANCY EXPOSURE TO COMMON-DETECT ORGANOPHOSPHATE 
ESTERS AND PHTHALATES AND MATERNAL THYROID FUNCTION  
 
5.1.  Overview 
Background. Contemporary human populations are exposed to elevated concentrations of 
organophosphate esters (OPEs) and phthalates. Some metabolites have been linked with altered thyroid 
function; however, inconsistencies exist across thyroid function biomarkers. Research on OPEs is sparse, 
particularly during pregnancy, when maintaining normal thyroid function is critical to maternal and fetal 
health. 
Aim. To characterize pregnancy exposure to OPE and phthalates in relation to maternal thyroid function, 
using a cross-sectional investigation of pregnant women nested within the Norwegian Mother, Father, and 
Child Cohort. 
Methods. We included 473 pregnant women, who were euthyroid and provided bio-samples at 17 weeks’ 
gestation (2004-2008). Four OPEs and six phthalate metabolites were measured from the urine; six 
thyroid function biomarkers were estimated from the blood. The relationships between thyroid function 
biomarkers and log-transformed concentrations of OPE and phthalate metabolites were characterized 
using general linear regression (GLM) and Bayesian Kernal Machine Regression (BKMR) while 
adjusting for confounders identified a priori. 
Results. We restricted our analysis to common-detect OPEs and phthalates (>94%): diphenyl phosphate 
(DPHP), di-n-butyl phosphate (DNBP), and all phthalate metabolites. In GLM, pregnant women with di-
iso-nonyl phthalate (DiNP) concentrations in the 75th percentile had a 0.37 ng/µg lower total 
triiodothyronine (TT3): total thyroxine (TT4) ratio (95% credible interval: [-0.59, -0.15]) as compared to 
those in the 25th percentile, possibly due to small but diverging influence on TT3 (-1.99 ng/dL [-4.52, 
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0.53]) and TT4 (0.13 µg/dL [-0.01, 0.26]). Similar trends were observed for DNBP and inverse 
associations were observed for DPHP, monoethyl phthalate, mono-iso-butyl phthalate, and mono-n-butyl 
phthalate. Most associations observed in GLM were attenuated towards the null in BKMR, except for the 
case of DiNP and TT3:TT4 ratio (-0.48 [-0.96, 0.003]).  
Conclusions. Maternal thyroid function varied modestly with DiNP, whereas results for DPHP varied by 
the type of statistical models. 
Keywords. Diphenyl phosphate; maternal thyroid function; pregnancy; mixtures; MoBa. 
5.2. Introduction  
 Organophosphate esters (OPEs) are widely used as plasticizers or flame retardants, with a steady 
increase in their production since the early 2000s1. Such temporal trends are partly due to OPEs’ 
recognition as replacements for a class of chemicals undergoing phase-out2, 3, i.e., polybrominated 
diphenyl ethers (PBDEs). The desirable property of OPEs is that they are rapidly metabolized and do not 
bioaccumulate; however, they also do not form covalent bonds and therefore easily leach or volatilize into 
the surrounding environment. Consequently, metabolites of several common-use OPEs have been 
detected frequently in human populations4, 5, 23, 34, 43-47. Particularly for diphenyl phosphate (DPHP), a 
metabolite of one of the most commonly-used OPEs, increasing human exposure has been reported over 
time48. Widespread exposure to OPEs raises concerns since recent studies suggest thyroid disruption 
properties6-8, 84, 192.  
 Epidemiological investigations on OPEs and thyroid function are relatively sparse, especially in 
pregnant women. Some OPEs have been associated with thyroid function in sub-fertile men9, 10 and office 
workers11, particularly DPHP and total triiodothyronine (TT3), though null findings have also been 
reported85, 86. Further, no studies to our knowledge have examined these associations in pregnant women, 
despite their differences in thyroid physiology with non-pregnant populations193, 194, and the importance of 
maintaining normal thyroid function with regards to maternal and fetal health12-18.  
 Characterizing the impacts of individual OPE metabolites is complicated by the correlated nature 
of exposure to environmental agents, since humans are simultaneously exposed to a mixture of chemicals. 
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Phthalates, which share common source products as OPEs30-33 and are widespread195, has also been 
associated with changes in thyroid homeostasis26, 27, 171, 196-204. Specifically, in a previous investigation of 
pregnant women in the Norwegian Mother, Father, and Child Cohort (MoBa), a factor dominated by 
mono-iso-butyl phthalate (MiBP), mono-n-butyl phthalate (MnBP), monobenzyl phthalate (MBzP) and 
another factor dominated by di-iso-nonyl phthalate (DiNP) were associated with measures of 
triiodothyronine27. However, the specific phthalate metabolite within the factor, that is strongly associated 
with thyroid function, remains unclear. Moreover, few studies of phthalates have attempted to account for 
correlated chemical exposures during pregnancy in relation to thyroid function, apart from within-class 
correlations among phthalates26, 27. Attempts to isolate effects of correlated exposures across chemical 
classes have also been limited in the investigations of OPEs and thyroid function, where other flame 
retardants but no other plasticizers, have been considered11, 86.  
 We sought to characterize the relationships between pregnancy exposure to OPEs and phthalates 
and maternal thyroid function in pregnant women, applying a mixtures approach to a cross-sectional 
subset of the MoBa.  
5.3. Material and methods 
 Study population 
MoBa is an ongoing prospective population-based cohort study of Norwegian-speaking women, 
conducted by the Norwegian Institute of Public Health172, 205. Between 1999-2008, pregnant women 
across Norway were recruited at their routine prenatal ultrasound visit (≈17 gestational weeks) and 
contributed urine and blood samples upon providing a written consent179. A total of 114,500 children, 
95,200 mothers, and 75,200 fathers are enrolled. 
The current study utilized a subset of MoBa enrollees who met the eligibility criteria: gave birth 
to a singleton without Down’s syndrome and cerebral palsy between April 2004 – January 2008 and 
resided within proximity to Oslo. A total of 33,050 pregnant women were eligible, and 555 mothers with 
available urine and blood specimen who completed the 36-month postnatal questionnaire were sampled, 
frequency-matched to an external population by birth year25. A total of 539 mothers who had measured 
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concentrations of thyroid function biomarkers and urinary OPE and phthalate metabolites were eligible 
for the current study. 
 Measurement of OPE and phthalate metabolites in urine 
Maternal urine samples were collected at 17 weeks’ gestation and shipped unrefrigerated to a 
central ISO-certified lab in Oslo overnight (Biobank), where the samples were stored at -80°C206. OPE 
and phthalate metabolites were analyzed at the Norwegian Institute of Public Health, in randomly-
assigned batches that contained quality control (QC) samples.  
Four OPE metabolites, i.e., DPHP, di-n-butyl phosphate (DNBP), bis(2-butoxyethyl) hydrogen 
phosphate (BBOEP), and bis(1,3-dichloro-2-propyl) phosphate (BDCIPP), were measured in the urine 
samples using ultra performance liquid chromatography (UPLC) coupled with quadrupole-time-of-flight 
(QTOF) by a modified method published previously182. The modification was applied in the sample 
preparation procedure and was adapted from an earlier published method183. In brief, labelled internal 
standards, 300 µL of water and 40 µL of formic acid were added to 300 µL of the urine sample. The OPE 
metabolites were extracted using Strata-X-AW 96-well plates (Phenomenenx, U.S.A.), which were 
conditioned first with 0.5 mL of MeOH and subsequently with 0.5 mL of H2O, both containing 1% 
formic acid. Samples were loaded, eluted by gravity and washed with 0.5 mL of MeOH to remove neutral 
interferences. The OPE metabolites were then eluted with 0.5 mL of acetone containing 5% triethylamine. 
Fifty microliters of water was added and the samples were evaporated with a gentle stream of nitrogen 
(10 L/hour) for 1 hour. Ten microliters was injected into the UPLC system as described elsewhere182. 
UPLC was performed using Acquity® C18 BEH c1olumn (50mm× 2.1 mm× 1.7 μm) from Waters Corp. 
(Milford, MA, U.S.A.). The metabolites were identified and quantified with tandem mass spectrometry 
using a Xevo® G2-S QTOF from Waters Corp. (Milford, MA, U.S.A.). All assays were conducted in 
batches, each of which contained 36-39 urine samples along with 8 in-house QC samples (3 spiked at 5 
ng/mL, 3 spiked at 15 ng/mL, and 2 blanks) and 10-11 laboratory-blinded QC aliquots from a 
homogenized urine pool. For the in-house spiked QC samples, the average of batch-specific CVs were 
low for DPHP, DNBP, and BBOEP (<10% at 15ng/mL; <13% at 5ng/mL), while slightly higher for 
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BDCIPP (14.7% at 15ng/mL; 16.4% at 5ng/mL). Laboratory-blinded pooled QC urine samples exhibited 
more variability, which is likely due to low OPE concentrations. Average concentrations of pooled urine 
QC samples (DPHP: 0.30µg/mL; DNBP: 0.10ng/mL; BBOEP: 0.08ng/mL; BDCIPP: 0.26ng/mL) were 
many orders of magnitude lower than the spiked concentrations and only slightly above the assay limits 
of detection (Supplementary Table 3).  
The analytic approach and quality control procedures for the measurement of phthalate 
metabolites have been previously reported25, 27. Briefly, we used on-line column switching liquid 
chromatography coupled with tandem mass spectrometry207 for the measurement of MiBP, MnBP, MBzP, 
monoethyl phthalate (MEP), mono-2-ethylhexyl phthalate (MEHP), mono-2-ethyl-5-hydroxyhexyl 
phthalate (MEHHP), mono-2-ethyl-5-oxoyhexyl phthalate (MEOHP), mono-2-ethyl-5-carboxypentyl 
phthalate (MECPP), mono-2-methylcarboxyhexyl phthalate (MMCHP), mono-4-methyl-7-hydroxyoctyl 
phthalate (OH-MiNP), mono-4-methyl-7oxooctyl phthalate (oxo-MiNP), and mono-4-methyl-7-
carboxyheptyl phthalate (cx-MiNP). The secondary metabolites of di(2-ethylhexyl)phthalate (DEHP) and 
DiNP were converted to molar concentrations and summed to estimate the total DEHP (∑DEHP) and 
DiNP (∑DiNP) exposure, respectively.  
To account for urinary dilution in each sample, we measured specific gravity, as defined by the 
ratio of the density of urine to water, using a pocket refractometer (PAL-10S) from Atago. Each 
individual’s concentrations of OPE metabolites were standardized for specific gravity using the equation 
below. Phthalate metabolite concentrations were standardized to specific gravity and batch-effect using 
our previously described approach25. 
𝑃𝑖𝑗





∗ : Specific gravity standardized concentration of ith OPE metabolite in jth individual’s urine 
𝑃𝑖𝑗: Raw concentration of i
th OPE metabolite in jth individual’s urine 
𝑆𝐺𝐺𝑀: Geometric mean of specific gravity in the total study population 
𝑆𝐺𝑗: Specific gravity of j
th person.  
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 Outcome Assessment 
Pregnant women provided blood samples at the same date they provided urine samples, 
approximately 17 weeks’ gestation. The collected blood samples were shipped unrefrigerated to the 
Biobank overnight for processing and storage at -80°C. Our previous quality control study assessed the 
impact of processing delays on thyroid function biomarkers and found it had a minimal impact184. TT3, 
triiodothyronine uptake, total thyroxine (TT4), thyroid stimulating hormone (TSH), and thyroid 
peroxidase autoantibodies (TPOAb) were measured from plasma using electrochemiluminescent 
immunoassays on the Roche Cobas e602 analyzer (Salt Lake City, Utah, USA). The inter-and intra-assay 
coefficients of variations (CV) were below 7% for TPOAb; <5% for TSH, triiodothyronine uptake, TT3, 
and TT4. 
Although TT3 and TT4 are reflective of the thyroid hormones in the blood, the majority of which 
are bound to plasma proteins, the hormones circulating in the free or unbound state are also important 
endpoints due to their relevance to fetal neurodevelopment. However, the direct measurement of the free 
thyroid hormones in plasma is likely to inaccurately reflect pregnancy concentrations due to large changes 
in the levels of plasma binding proteins and total thyroid hormones, both of which are highly variable in 
pregnant women208, 209. Alternatively, indices of free triiodothyronine and thyroxine (FT3i; FT4i) can be 
calculated with triiodothyronine uptake (equation 1), which measures the binding capacity of thyroxine 
binding globulin in blood. These indices and the gold-standard (free thyroxine measurement in serum) 
have shown spearman correlations of 0.97-0.99 in our previous investigation184. FT4i, TSH, and TPOAb 
were used to identify participants with abnormal thyroid function biomarkers concentrations, which were 
considered in the construction of the euthyroid study population as described in the analytic approach. 
𝐹𝑇3𝑖(𝑜𝑟 𝐹𝑇4𝑖) = 𝑇𝑇3(𝑜𝑟 𝑇𝑇4) ×
𝑇3 𝑢𝑝𝑡𝑎𝑘𝑒
𝑀𝑒𝑑𝑖𝑎𝑛(𝑇3 𝑢𝑝𝑡𝑎𝑘𝑒)
 (Equation 1) 
We also calculated the ratio of TT3 toTT4 (TT3:TT4), which may reflect a mechanism of thyroid 
homeostasis that is different from hyper- or hypo-activation of the thyroid gland210, 211. 
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 Covariate Assessment 
We obtained covariate data from the MoBa questionnaire that was mailed to participants at 15 
weeks’ gestation, from the food frequency questionnaire that mothers completed at ~22 weeks’ gestation, 
and from data linkage with the Medical Birth Registry of Norway (MBRN). From the 15 weeks’ 
questionnaire, we obtained maternal characteristics reported by mothers: preexisting thyroid disease, 
thyroid medication, education, depression before or during pregnancy, smoking during the first or second 
trimester of pregnancy, and alcohol intake during pregnancy.  
Maternal iodine and selenium intake during pregnancy were estimated from a food frequency 
questionnaire that mothers completed at 22 weeks’ gestation187. Briefly, pregnant women responded to a 
semi-quantitative questionnaire that is intended to characterize diet during the first four months of 
pregnancy via 255 food items and additional dietary supplements. The dietary iodine and selenium 
intakes calculated from the food frequency questionnaire (g/day) were moderately correlated with those 
from four-day weighed food diaries (?̂? for iodine: 0.46; ?̂? for selenium: 0.28) or 24-hour urine (?̂? for 
iodine: 0.38)187, 188. 
Maternal age at delivery, preexisting thyroid disease, and parity were obtained by linkage with 
MBRN. We also obtained the year and month of biosample collection. 
 Ethics Data collection for MoBa was approved by the Norwegian Data 
The establishment of MoBa and initial data collection was based on a license from the Norwegian 
Data Protection Agency and approval from The Regional Committees for Medical and Health Research 
Ethics. The MoBa cohort is now based on regulations related to the Norwegian Health Registry Act. The 
current study was approved by the Norwegian Data Inspectorate and the Norwegian Committee for 
Medical and Health Research Ethics (REC). The current study was approved by the Norwegian REC and 
the Institutional Review Board at the University of North Carolina Chapel Hill.  
 Analytic approach 
Our primary analysis was restricted to the euthyroid population, which excluded women with 1) 
self-reported pre-existing thyroid disease diagnosis (N=25); 2) self-reported taking thyroid medication 
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(N=15); or 3) measured biomarkers of TSH, TPOAb, and FT4i concentrations that could imply thyroid 
dysfunction (N=15; TSH<0.19 and/or FT4i>14.03; FT4i<7.73; TSH>4.06 and TPOAb>9). This 
restriction resulted in a euthyroid study population of 489 women out of 539 eligible pregnant women. 
We undertook a complete case analysis of 473 euthyroid women with complete data since missingness 
was minimal (N=16; 3%) and limited to maternal smoking during pregnancy (n = 6), age (n =2), 
education (n =7), parity (n =2), dietary iodine (n = 6), and dietary selenium (n =6). Given the infrequent 
detection of some OPE metabolites in the current study population, we retained only the highly-detected 
OPE metabolites (>94%) and substituted concentrations below the limit of detection (LOD) with 
LOD/√2212.  
A directed acyclic graph was constructed and minimally sufficient adjustment sets were 
identified. This adjustment set included year, maternal age, education, parity, dietary iodine, dietary 
selenium, depression, smoking, and the urinary concentrations of phthalate metabolites. Adjusting for all 
covariates in the minimally sufficient adjustment set and co-exposures, we modeled the relationship 
between log-transformed OPE and phthalate metabolites and thyroid function biomarkers using general 
linear regression (GLM). All results are presented as the absolute difference in thyroid function 
biomarkers per interquartile range increase in logged-exposure. We additionally conducted Bayesian 
Kernal Machine Regression (BKMR; R package ‘bkmr’), which allows flexible modeling of dose-
response in the presence of multiple correlated exposures213. From the BKMR models, we extracted using 
the default (“approximate”) and “exact” method the absolute difference in thyroid function biomarkers 
expected with increasing an OPE or phthalate metabolite from its 25th to the 75th percentile while 
keeping all other metabolites constant at their 25th percentile and adjusting for confounders. We also 
present their corresponding 95% credible intervals as well as the posterior inclusion probabilities (PIPs). 
Sensitivity analyses were conducted to examine the robustness of findings. First, we examined 
the relationships between OPE metabolites and thyroid function biomarkers in the total population with 
complete data (i.e., inclusive of non-euthyroid participants; N=522). We also explored the impact of 
exposure transformation and alternative definitions of OPE-phthalate mixtures in BKMR. Batch-effect 
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was examined using a leave-one-out approach, where the main analysis was repeated with successive 
removal of one batch at a time. 
All analyses were performed with R v.4.0.0, using version 9 of the MoBa quality assured dataset. 
5.4. Results 
 Descriptive Characteristics of the Study Population 
The majority of women were in their 30s, completed college or more, did not report depression 
before or during pregnancy, did not report smoking during pregnancy, and had low dietary intakes of 
iodine and selenium (Table 6).  
DPHP (96%>LOD), DNBP (94%>LOD), and BBOEP (51%>LOD) were detected in more than 
half of the urine samples (Table 7). The DPHP concentrations exceeded the limit of quantification (LOQ) 
in most cases (93%), while only 18% of the detectable BBOEP concentrations were above LOQ. The 
correlations across OPE metabolites and between OPE and phthalate metabolites were low (?̂?<0.30; 
Supplementary Figure 1).  
 Potential Thyroid Function Disruption from Models that Simultaneously 
Included 2 OPEs and 6 Phthalates  
In both GLM and BKMR models that considered confounding by co-occurring metabolites and 
covariates, we observed an inverse association between ∑DiNP and TT3:TT4 ratio. Specifically, pregnant 
women with ∑DiNP concentration in the 75th percentile had a 0.37 ng/µg [95% credible interval: -0.59,  
-0.15] lower TT3:TT4 ratio compared to those in the 25th percentile when using GLM; while the 
association was slightly larger using BKMR (exact: -0.48 ng/µg [-0.96, 0.003]; approx.: -0.57 ng/µg [-
0.90, -0.24]; PIP: 0.869; Table 8; Supplementary Figure 6). In GLM models that separately considered 
TT3 or TT4 concentrations as dependent variables, higher ∑DiNP was associated with imprecise and 
small but diverging difference in thyroid hormones (TT3: -1.99 ng/dL [-4.52, 0.53]; TT4: 0.13 µg/dL [-
0.01, 0.26]; Table 8). These directions of association were also found in BKMR models, however, the 
estimates were near null (exact TT3: -0.16 ng/dL [-1.74, 1.41]; exact TT4: 0.01 µg/dL [-0.08, 0.09];Table 
8) and PIP were low (TT3: 0.009; TT4: 0.010; Supplementary Figure 2). Similar trends, although smaller 
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and more imprecise, were observed for MEP and MnBP in GLM models, which were attenuated to near-
null in BKMR. A different pattern of association were observed for MBzP using GLM, where imprecise 
and small positive associations were observed with individual thyroid hormone biomarkers but the 
associations with TT3:TT4 ratio were near null (Table 8). In BKMR, we observed no notable 
relationships with any other phthalate metabolites and thyroid function biomarkers (Table 8; 
Supplementary Figure 2). 
Among the OPE metabolites, we observed that DPHP showed similar patterns of associations 
across thyroid function biomarkers as DiNP in GLM, although the directions of association were inverse. 
Specifically, pregnant women with DPHP concentration in the 75th percentile had a 0.34 ng/µg [0.08, 
0.60] higher TT3:TT4 ratio as compared to those in the 25th percentile; while imprecise and small but 
diverging differences were observed with the individual thyroid hormones (TT3: 1.32 ng/dL [-1.68, 4.32]; 
TT4: -0.14 µg/dL [-0.30, 0.02]; Table 8). However, all associations were attenuated to near-null with 
BKMR (DPHP and TT3:TT4 ratio: exact: 0.06 ng/µg [-0.27, 0.39]; approx: 0.32 ng/µg [0.04, 0.61]; PIP: 
0.135; Table 8; Supplementary Figure 2). Similar but weaker and inverse associations were observed for 
DNBP when using GLM, which was also attenuated to near-null in BKMR (Table 8; Supplementary 
Figure 2). 
 Sensitivity Analysis  
When the primary analyses were repeated inclusive of 49 non-euthyroid women (n=522), we 
found inferentially similar associations (Supplementary Table 4). We observed that the shape and 
magnitude of the dose-response function for some phthalate metabolites and TT3:TT4 ratio were 
somewhat sensitive to exposure transformation methods (Supplementary Figure 3). The interpretation of 
results remained consistent when an alternative definition of mixtures was used (Supplementary Figure 4) 
or in the investigation of batch-effect by successive removal of analytic batches (data not shown). 
5.5. Discussion 
We characterized the relationships between urinary OPE and phthalate metabolites and maternal 
thyroid function among pregnant, euthyroid women. Using traditional analytic approaches, we observed 
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that higher DPHP during pregnancy was associated with small but diverging differences in individual 
thyroid hormones and a higher TT3:TT4 ratio; while inverse but stronger associations were observed for 
∑DiNP. We also found slightly higher concentrations of thyroid hormones with higher MBzP. However, 
when BKMR was employed, most associations attenuated towards the null, except for ∑DiNP and 
TT3:TT4 ratio. Using BKMR, we found no notable associations between OPEs and thyroid function. 
Subtle but diverging differences in individual thyroid hormones and substantial differences in the 
TT3:TT4 ratio could be suggestive of a thyroid disruption mechanism that is distinct from hyper- or 
hypo-active stimulation of the thyroid gland. TT3, the active form of thyroid hormones, is produced at an 
approximate rate of 40 nmoles per day in euthyroid adults; of which only 5nmoles are directly secreted 
from the thyroid gland, and the remainder is derived from peripheral conversion of TT4214. The higher 
TT3:TT4 ratio observed with elevated DPHP in GLM could be a consequence of more peripheral 
conversion215, 216, or increased production of triiodothyronine by the thyroid gland, which can be observed 
in iodine-deficient217, 218 or hyperthyroid individuals219. Since over 70% of our study participants had low 
dietary iodine intake (<150 microgram/day), preferential secretion of triiodothyronine and peripheral 
conversion of thyroxine are both plausible explanations for our results. The biological plausibility of 
peripheral thyroxine to triiodothyronine conversion has been reported in experimental settings, which 
involves the up-regulation of deiodinase type2 (dio2) gene expression or abundant delivery of thyroxine 
to target tissues6, 7. For example, up-regulated dio2 has been observed in the thyroid gland, brain, and 
liver of adult female zebrafish after 14-day exposure to triphenyl phosphate (TPHP), which is one of the 
parent compounds for DPHP7. DPHP and its parent compounds have also been reported to enhance the 
binding of thyroxine to transthyretin, a transport protein that delivers thyroxine to target cells6. Further, 
there may exist multiple additional target points for OPEs and phthalates to affect the hypothalamic-
pituitary-thyroid axis220, which regulates the thyroid gland through complex feedback loops221. 
Our findings are difficult to compare directly to previous studies of OPE exposure and thyroid 
function due to the absence of studies that included pregnant women. Previous studies had examined sub-
fertile men9, 10, office workers11, rural community residents85, and electronic waste recycling workers86, of 
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which only a subset included female participants11, 85, 86. Most studies reported higher TT3 and some 
reported imprecise but slightly higher free or total thyroxine9-11, 86. We also observed imprecise but 
slightly higher TT3 in GLM, however, we additionally observed a slightly lower TT4 in GLM and no 
notable relationship in BKMR. Given the imprecise and modest estimates that were variably observed 
across studies, we cannot rule out an overall null association between thyroid function and DPHP. 
However, it should be noted that our study approach differed in potentially important ways from prior 
studies. We excluded non-euthyroid individuals since their measured thyroid may have been affected by 
medical interventions, we included a comprehensive set of thyroid function biomarkers including free 
indices and the TT3:TT4 ratio; and we accounted for confounding by phthalate exposures, another class 
of thyroid-active compounds. Differences in analytic methods may in part explain heterogeneity in results 
across studies, together with the biological differences in the populations as attributed to biological sex 
and pregnancy. Since pregnancy induces changes to thyroid physiology193, 194, it is possible that OPE’s 
impact on thyroid function is different in pregnant populations as compared to non-pregnant populations. 
Such relationships between OPEs and thyroid function may vary throughout pregnancy, given the 
variability in thyroid hormone concentrations throughout pregnancy194. Further attention is needed to the 
potential impact of OPEs and thyroid homeostasis, given the increasing utilization of OPEs in consumer 
products, and the rising exposures to human populations48.  
Our study is unique in that we considered two families of rapidly metabolized, thyroid-active 
chemicals on thyroid homeostasis during pregnancy. Further, the application of BKMR was able to 
reduce the dimension of correlated exposures and identify the major drivers of any associations. We also 
observed potential thyroid disruption by specifically ∑DiNP and MBzP, which is in line with our 
previous investigation of phthalates that was conducted using a larger sub-population within MoBa27. In 
the previous study, TT3 was positively associated with a latent factor dominated by DEHP and DINP 
while negative associations were observed with a latent factor dominated by MiBP, MnBP, and MBzP. 
The associations observed for MBzP implies overactive thyroid function and is also consistent with 
experimental evidence of thyroid hyperfunction222. It is possible that associations observed for DiNP 
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could be attributable to their T3 antagonist activities resulting from competitively binding to the thyroid 
receptor223, however, toxicological and epidemiological research on DiNP remains sparse.  
Several other studies have also investigated the relationship between phthalate exposure and 
thyroid function during pregnancy, however, the results remain inconclusive26, 171, 197-199. Notable 
differences in thyroxine or TSH had been reported in relation to MEP, MBP, or MCPP, although the 
influential metabolite was not always consistent across studies. This is in contrast to our study, where we 
did not observe notable differences in TSH; rather imbalance between TT3 and TT4 was observed in 
relation to ∑DiNP in both GLM and BKMR while elevated TT3 and TT4 were observed with higher 
MBzP in GLM. Similar to our study, MBzP was positively associated with TT4 in serum in studies in 
Puerto Rico199, Boston198, Cincinnati26, and Taiwan171, but not in a study in Taiwan where MBzP was 
mostly non-detectable197. The relationship was particularly strong in cross-sectional investigations using 
urine collected at 16-20 weeks’ gestation26, 198, 199, which is in line with our findings and suggests that the 
strength of associations may be specific to gestational weeks. 
Our study has several strengths. This is the first study to examine the impact of OPE exposure on 
thyroid function in pregnant women, whose affected thyroid function could influence not only maternal 
health but also fetal development12-18. By nesting our study within a large pre-existing pregnancy cohort, 
MoBa, we were able to take advantage of important determinants of thyroid health, including validated 
measures of habitual iodine intake, and conduct analyses that were limited to euthyroid individuals. The 
MoBa participants also had various thyroid function biomarkers that were previously validated for 
pregnant women184, which enabled us to rigorously characterize the relationship between gestational 
thyroid function and OPE metabolites. We included OPE metabolites that have not been previously 
investigated in epidemiological settings, despite their ubiquity, and flexibly modeled the exposure-
response relationships utilizing BKMR, which allows for non-linear associations and utilizes variable 
selection to accommodate correlated exposures. Although phthalates are recognized as an independent 
risk factor for thyroid health and may share the exposure pathway with OPEs due to their similar usage as 
plasticizers, they have not been considered as confounders in previous investigations. Lastly, this is the 
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largest study of its kind and is the first to be conducted outside of North America, spanning an earlier 
period of years (2003-2007) compared to most previous studies11, 85, 86, which allowed us to examine the 
health impact of OPEs exposure in low-exposure settings. 
Our study also had some limitations. First, DPHP lacks specificity as a biomarker of OPE 
exposure since it aggregates exposures to multiple parent OPEs, including resorcinol bis-diphenyl 
phosphate50, ethylhexyl diphenyl phosphate49, and TPHP49, 56. If only a subset of DPHP parent compounds 
exhibits thyroid disrupting properties, the associations estimated with DPHP may not accurately reflect 
that of the thyroid active compound. However, both DPHP, as well as TPHP, have been reported to 
exhibit thyroid-disrupting properties in vitro6, in which case using DPHP as an integrated biomarker can 
be helpful to identify relevant associations. A consequence of OPE exposure on thyroid function would be 
noteworthy because maternal thyroid function is particularly important in the first trimester when the 
fetus is entirely reliant on maternal supply224. Failure to maintain normal thyroid function can affect fetal 
brain development and increase the risk of pregnancy complications12-18, 225.   
Another limitation is that MoBa only collected one urine and blood sample during pregnancy, at 
the same visit. Since thyroid physiology is highly variable throughout pregnancy, we are unable to 
identify potential thyroid-disruption at different periods of pregnancy208, 209 or lagged-effects of exposure. 
However, such co-incident measurements are relevant to investigate thyroid function disruption of OPEs 
exposure due to the short half-lives of both the exposures and the outcome biomarkers, albeit the 
limitation that this study was cross-sectional. Lastly, we did not adjust for PBDEs, another family of 
thyroid-active chemicals. Although PBDEs have also been detected in MoBa pregnant women226, 227, the 
concentrations are at least an order of magnitude lower than that in the United States228 and previous 
studies of PBDEs in Norway did not find associations with neonatal thyroid function229 nor ADHD230. 
Therefore, it is possible that PBDE exposure in this study population may not exceed the threshold to 
exhibit adverse health effects.  
5.6. Conclusion 
Pregnancy exposure to ∑DiNP was associated with imbalance between T3 and T4. Similar but 
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inverse associations were observed for DPHP, although the estimates and the level of uncertainty varied 





5.7.  Tables and Figures 
Table 6 Descriptive characteristics of the euthyroid study population (N=473). 
Characteristic Category N (%) 
Maternal age <20 3 (1 %) 
 20-29 176 (37 %) 
 30-39 285 (60 %) 
 40≤ 9 (2 %) 
Maternal education > College completed 148 (31 %) 
 College completed 207 (44 %) 
 < College completed 108 (23 %) 
 Other education 10 (2 %) 
Parity  Nulliparous 234 (49 %)  
Multiparous 239 (51%) 
Depression before/during pregnancy Yes 27 (6 %) 
 No 446 (94%) 
Dietary iodine intake ≥150 microgram/day 134 (28 %) 
 <150 microgram/day 339 (72 %) 
Dietary selenium intake ≥60 microgram/day 144 (40%) 
 <60 microgram/day 329 (70%) 
Smoking reported at None during pregnancy 405 (86%) 
17 weeks Any during pregnancy 68 (14 %) 
Year of sample collection 2003 11 (2 %) 
 2004 76 (16 %) 
 2005 150 (32 %) 
 2006 161 (34 %) 
 2007 75 (16 %) 
Month of sample collection May - August 210 (44%) 
 September – November 159 (34%) 





Table 7 Descriptive characteristics of the exposure and outcome biomarkers in the euthyroid study 
participants (N=473). 
Class Biomarker GM ± SD Median (25th - 75th percentile) 
Thyroid  
Function* 
TSH (mU/L) 1.60 ± 1.6 1.63 (1.20 - 2.18) 
TT3 (ng/dL) 163.20 ± 1.2 163 (147 - 181) 
TT4 (µg/dL) 10.40 ± 1.1 10.36 (9.53 - 11.39) 
TT3:TT4 ratio (ng/µg) 15.86 ± 2.3 15.81 (14.17 - 17.34) 
FT3i (ng/dL) 162.17 ± 1.1 162 (147.07 - 178) 
FT4i (µg/dL) 10.33 ± 1.1 10.29 (9.42 - 11.34) 




DPHP (µg/L) 0.52 ± 2.8 0.55 (0.29 - 0.99) 
DNBP (µg/L) 0.28 ± 2.2 0.24 (0.17 - 0.40) 
BBOEP (µg/L) 0.09 ± 2.4 0.08 (<LOD - 0.15) 




MEP (µg/L) 102.45 ± 4.4 101.18 (32.97 - 305.21) 
MiBP (µg/L) 18.74 ± 2.5 17.07 (9.74 - 32.20) 
MnBP (µg/L) 18.67 ± 2.4 17.53 (11.79 - 30.98) 
MBzP (µg/L) 4.68 ± 2.5 4.26 (2.56 - 7.85) 
MEHP (µg/L) 11.27 ± 2.1 10.28 (7.07 - 16.61) 
MEHHP (µg/L) 14.26 ± 2.5 12.89 (8.52 - 21.13) 
MEOHP (µg/L) 9.60 ± 2.4 8.78 (5.71 - 14.37) 
MECPP (µg/L) 21.08 ± 2.0 18.61 (14.06 - 25.84) 
MMCHP (µg/L) 21.22 ± 1.9 18.33 (14.07 - 26.89) 
∑DEHP (mmol/L) 0.27 ± 2.0 0.24 (0.18 - 0.34) 
OH-MiNP (µg/L) 1.07 ± 2.1 0.95 (0.69 - 1.44) 
oxo-MiNP (µg/L) 1.24 ± 2.4 1.04 (0.70 - 1.78) 
cx-MiNP (µg/L) 3.69 ± 1.7 3.54 (2.46 - 4.77) 
∑DiNP (mmol/L) 0.02 ± 1.9 0.02 (0.01 - 0.03) 
*Arithmetic mean and standard deviation presented instead of GM ± SD. 
**DPHP LOD: 0.03 (97%>LOD); DNBP LOD: 0.07 (94%>OD); BBOEP LOD: 0.05 (52%>LOD); 
BDCIPP LOD: 0.17 (21%>LOD). 
Notes: only OPE metabolites were measured below LOD for some participants, and therefore was 
substituted with LOD/√2. 
Abbreviations: triiodothyronine, T3; thyroxine, T4; Thyroid stimulating hormone, TSH; Diphenyl 
phosphate, DPHP; Di-n-butyl phosphate, DNBP; Bis(2-butoxyethyl) hydrogen phosphate, BBOEP; 
Bis(1,3-dichloro-2-propyl) phosphate, BDCIPP; specific gravity, SG; geometric mean, GM; geometric 
standard deviation, SD; monoethyl phthalate, MEP; mono-iso-butyl phthalate, MiBP; mono-n-butyl 
phthalate, MnBP; monobenzyl phthalate, MBzP; molar sum of di(2-ethylhexyl)phthalate metabolites, 
∑DEHP; molar sum of di-iso-nonyl phthalate metabolites, ∑DiNP 
 
 
Table 8 Absolute difference in thyroid hormones associated with a difference in log-transformed concentration of each individual metabolite from 
the 25th to 75th percentile in euthyroid pregnant women in MoBa 2003-2008 (N=473), while keeping adjustment factors constant*. 
Model 
OPE metabolites Phthalate metabolites 
DPHP DNBP  MEP MiBP MnBP MBzP ∑DEHP ∑DiNP 















 (-0.17, 0.26) 
-0.37 
































 (-0.32, 0.35) 
0.01 
 (-0.23, 0.26) 
-0.57  
(-0.90, -0.24) 













 (-1.28, 6.14) 
-0.47 
















































 (-0.18, 0.23) 
-0.03 


















 (-0.01, 0.01) 
0.005 








 (-0.25, 0.03) 
0.10  
(-0.03, 0.24)  
-0.03 











TSH (mU/L)         
GLM 
0.05 
 (-0.05, 0.14) 
-0.02 
 (-0.10, 0.06)  
-0.02 




 (-0.12, 0.09) 
-0.02 
 (-0.14, 0.10) 
0.02 
 (-0.06, 0.10) 
0.03 






 (-0.02, 0.02)  
0.00004 
 (-0.01, 0.01) 
0.001 
 (-0.02, 0.03) 
0.003 
 (-0.03, 0.04) 
0.0002 
 (-0.02, 0.02) 
0.002 












 (-0.07, 0.12) 
0.001 
 (-0.10, 0.09) 
-0.01 
 (-0.10, 0.08) 
0.01 
 (-0.06, 0.08) 
0.01 
 (-0.07, 0.10) 
*All models included 2 OPE and 6 phthalate metabolites simultaneously adjusted for year, parity, season of specimen collection, education, age, 
selenium, iodine, depression, and smoking. BKMR estimates calculated by contrasting the posterior outcome levels at 25th and 75th exposure 






5.8.  Supporting materials 
 
Supplementary Figure 1 Spearman correlation coefficients across OPE and phthalate metabolites in the 
euthyroid population (n=473). 
Abbreviations: Diphenyl phosphate, DPHP; Di-n-butyl phosphate, DNBP; Bis(2-butoxyethyl) hydrogen 
phosphate, BBOEP; Bis(1,3-dichloro-2-propyl) phosphate, BDCIPP; monoethyl phthalate, MEP; mono-
iso-butyl phthalate, MiBP; mono-n-butyl phthalate, MnBP; monobenzyl phthalate, MBzP; molar sum of 















Supplementary Figure 2 Relationship between all thyroid function biomarkers in maternal plasma and individual metabolites in the euthyroid 
population (N=473), modeled with the Bayesian kernel machine regression (50,000 iterations). All models included 2 OPE and 6 phthalate 
metabolites while adjusting for year, maternal age, education, depression before or during pregnancy, dietary iodine and selenium intake, smoking 
during pregnancy, parity, and season of sample collection. In each plot, we denoted the posterior inclusion probabilities (bottom-right) and exposure 
percentiles (orange: 25th; purple: 50th; and green: 75th). 
Abbreviations: Total triiodothyronine, TT3; total thyroxine, TT4; diphenyl phosphate, DPHP; Di-n-butyl phosphate, DNBP; monoethyl phthalate, 
MEP; mono-iso-butyl phthalate, MiBP; mono-n-butyl phthalate, MnBP; monobenzyl phthalate, MBzP; molar sum of di(2-ethylhexyl)phthalate 



















Supplementary Figure 3 Relationship between total triiodothyronine in maternal plasma and select metabolites in the euthyroid population 
(N=473) using alternative exposure transformations, modeled with the Bayesian kernel machine regression (50,000 iterations). All models 
included 2 OPE and 6 phthalate metabolites while adjusting for year, maternal age, education, depression before or during pregnancy, dietary 
iodine and selenium intake, smoking during pregnancy, parity, and season of sample collection. In each plot, we denoted the posterior inclusion 
probabilities (bottom-right) and exposure percentiles (orange: 25th; purple: 50th; and green: 75th). 
Abbreviations: Total triiodothyronine, TT3; diphenyl phosphate, DPHP; Di-n-butyl phosphate, DNBP; monoethyl phthalate, MEP; mono-iso-butyl 
phthalate, MiBP; mono-n-butyl phthalate, MnBP; monobenzyl phthalate, MBzP; molar sum of di(2-ethylhexyl)phthalate metabolites, ∑DEHP; 











Supplementary Figure 4 Comparison of BKMR models using TT3:TT4 ratio as the outcome in the 
euthyroid population (N=473; 50,000 iterations): (a) no phthalates adjustment, (b) the main model 
inclusive of 2 frequently detected OPE metabolites and all phthalate metabolites, and (c) inclusion of low-
detect OPE metabolites. All models adjusted for year, maternal age, education, depression before or 
during pregnancy, dietary iodine and selenium intake, smoking during pregnancy, parity, and season of 
sample collection. In each plot, we denoted the posterior inclusion probabilities (bottom-right) and 
exposure percentiles (orange: 25th; purple: 50th; and green: 75th). 
Abbreviations: Total triiodothyronine, TT3; total thyroxine, TT4; Bayesian kernel machine regression, 
BKMR, diphenyl phosphate, DPHP; Di-n-butyl phosphate, DNBP; Bis(2-butoxyethyl) hydrogen 
phosphate, BBOEP; Bis(1,3-dichloro-2-propyl) phosphate, BDCIPP; monoethyl phthalate, MEP; mono-
iso-butyl phthalate, MiBP; mono-n-butyl phthalate, MnBP; monobenzyl phthalate, MBzP; molar sum of 





Supplementary Table 1 Descriptive statistics of the laboratory-blinded pooled urine quality-control samples 
















DPHP 0.03 100 0.30 ± 0.22 7 74.6 31.8 
DNBP 0.07 68.3 0.11 ± 0.12 5 111 49.9 
BBOEP 0.07 36.6 0.08 ± 0.13 5 170 69 
BDCIPP 0.17 51.2 0.26 ± 0.54 1 208 54.6 
Abbreviations:  
Diphenyl phosphate, DPHP; Di-n-butyl phosphate, DNBP; Bis(2-butoxyethyl) hydrogen phosphate, 







Supplementary Table 2 Sensitivity analysis inclusive of 49 non-euthyroid women (N=522): absolute difference in thyroid hormones associated with 
a difference in log-transformed concentration of each individual metabolite from the 25th to 75th percentile, keeping adjustment factors constant*. 
Outcome 
OPE metabolites  Phthalate metabolites 
DPHP DNBP  MEP MiBP MnBP MBzP ∑DEHP ∑DiNP 





 (-0.44, 0.04)  
0.24 




 (-0.19, 0.43) 
0.05 










 (-0.08, 0.07)  
0 




 (-0.15, 0.18) 
0.35 










(-0.37, 0.1)  
0.01 










 (-1.06, -0.31) 













 (-1.07, 5.98) 
-0.62 
 (-3.02, 1.77) 
-2.40 










 (-1.13, 1.3) 
0.06 
 (-0.9, 1.02) 
1.01 










(-2.85, 1.86)  
0 




 (-1.96, 3.73) 
2.62 
 (-1.00, 6.25) 
-0.28 
 (-1.72, 1.17) 
-1.96 
 (-4.59, 0.67) 































 (-0.04, 0.04) 
-0.00004 
 (-0.02, 0.02) 
0.01 










 (-0.25, 0.10) 
-0.003 






 (-0.03, 0.25) 





(-0.09, 0.09)  
-0.03 
 (-0.15, 0.09) 
0.02 
 (-0.11, 0.15) 
-0.02 
 (-0.13, 0.10) 
0.005 








 (-0.01, 0.01) 
0.0003 
 (-0.02, 0.02)  
-0.0001 
 (-0.01, 0.01) 
0.0001 
 (-0.02, 0.02) 
0.001 
 (-0.02, 0.03) 
0.0001 
 (-0.02, 0.02) 
-0.0003 
 (-0.02, 0.02) 
-0.01 




 (-0.07, 0.09) 
0.001 
 (-0.08, 0.08)  
-0.02 




 (-0.10, 0.09) 
0.01 
 (-0.09, 0.10) 
0.001 











*All models included log-transformed concentrations of 2 OPE and 6 phthalate metabolites simultaneously while adjusting for year, dietary 
selenium, dietary iodine, parity, depression, the season of specimen collection, education, age, and smoking during pregnancy. BKMR estimates 
were calculated by contrasting the posterior outcome levels at 25th and 75th exposure percentiles; GLM estimates were calculated by scaling the 
regression coefficients by interquartile range. 
Abbreviations: Total triiodothyronine, TT3; total thyroxine, TT4; Thyroid stimulating hormone, TSH; Diphenyl phosphate, DPHP; Di-n-butyl 
phosphate, DNBP; monoethyl phthalate, MEP; mono-iso-butyl phthalate, MiBP; mono-n-butyl phthalate, MnBP; monobenzyl phthalate, MBzP; 








CHAPTER 6. PRENATAL EXPOSURE TO ORGANOPHOSPHATE ESTERS AND THE RISK 
OF CHILDHOOD ADHD 
 
6.1.  Overview 
Background. Organophosphate esters (OPEs) are a class of conventional flame retardants in common 
use. OPEs can easily leach from materials, resulting in human exposure. Increasing concentrations have 
been reported in human populations over the past decade. Recent studies have linked prenatal OPE 
exposure to hyperactivity and attention problems in children. Such behaviors are often found among 
children with attention-deficit hyperactivity disorder (ADHD), however, no study has investigated OPEs 
in relation to clinically assessed ADHD. 
Objective. To evaluate prenatal exposure to OPEs as risk factors for clinically assessed ADHD using a 
case-cohort study nested within the Norwegian Mother, Father, and Child Cohort (MoBa). 
Methods. We included in the case group 295 ADHD cases obtained via linkage with the Norwegian 
Patient Registry, and the sub-cohort group 555 children sampled at baseline, irrespective of their ADHD 
case status. Prenatal concentrations of OPE metabolites were measured in maternal urine collected at 17 
weeks of gestation, and included diphenyl phosphate (DPHP), di-n-butyl phosphate (DNBP), bis(2-
butoxyethyl) hydrogen phosphate (BBOEP), and bis(1,3-dichloro-2-propyl) phosphate (BDCIPP). We 
estimated risk ratios (RRs) and the corresponding 95% confidence intervals [95% CI] using logistic 
regression, adjusting for the season of urine collection, child sex, birth year, and maternal depression, 
education, and sum of urinary di(2-ethylhexyl) phthalate metabolites (∑DEHP) concentration during 
pregnancy. To assess the overall impact of simultaneously increasing exposure to all chemical 
constituents of an OPE-phthalate mixture, quantile based g-computation was implemented. The mixture 




considered effect measure modification by child sex and polymorphisms in genes encoding paraoxonase 1 
(PON1) and cytochrome P450 (P450) enzymes. Mediation analysis was conducted using thyroid function 
biomarkers estimated from maternal blood collected at 17 weeks of gestation. 
Results. DPHP was detected in nearly all samples (98%), with a higher geometric mean among the case 
group (0.70 µg/L) as compared to the sub-cohort (0.52 µg/L). DNBP was commonly detected as well 
(94%), while BBOEP (51%) and BDCIPP (21%) were detected less frequently. A higher risk of ADHD 
was observed in children with greater than median exposure to DPHP during pregnancy (RR: 1.38 [95% 
CI: 0.96, 1.99]), which was slightly higher among girls (2.04 [1.03, 4.02]) and among children of mothers 
with PON1 Q192R genotype QR (1.69 [0.89, 3.19]) or PON1 Q192R genotype RR (4.59 [1.38, 15.29]). 
Part of the relationship between DPHP and ADHD (total RR: 1.34 [0.90, 2.02]) was mediated through 
total triiodothyronine to total thyroxine ratio (natural direct effect: 1.29 [0.87, 1.94]; natural indirect 
effect: 1.04 [1.00, 1.10]; 12.48% mediated). We also observed an elevated risk of ADHD in relation to 
BDCIPP detection during pregnancy (1.50 [0.98, 2.28]). We did not observe notable differences in 
ADHD by DNBP (0.88 [0.62, 1.26]) or BBOEP (1.03 [0.73, 1.46]) during pregnancy. Simultaneously 
decreasing all constituents of common-detect OPE-phthalate mixture, specifically DPHP, DNBP, and 6 
phthalate metabolites, by a quartile resulted in an ADHD RR of 0.68 [0.64, 0.72]. 
Conclusion. Prenatal exposure to DPHP and BDCIPP may increase the risk of ADHD. For DPHP, we 
observed potential modification by child sex and maternal PON1 Q192R genotype and partial mediation 
through maternal thyroid hormone imbalance at 17 weeks gestation. 
6.2.  Introduction 
Concurrent with the decline in usage of polybrominated diphenyl ethers2, 3, a class of persistent 
flame retardants, was an increase in the production and usage of organophosphate esters (OPEs) as flame 
retardants or plasticizers. Although OPEs do not bioaccumulate in the environment, they tend to easily 
leach and volatilize from the materials to which they are added, resulting in widespread human exposure1. 
Several OPE metabolites are commonly detected, such as diphenyl phosphate (DPHP), bis(1,3-dichloro-




phosphate (BBOEP)4, 5; however, their impacts on human health and disease are not well understood. 
An increasing number of studies evidence suggests that exposure to OPEs may affect child 
neurobehavioral development. Neurotoxic19, 20 and endocrine disruptive properties8, 192 have been 
identified in experimental settings. Further, recent epidemiological studies link OPE exposure with 
externalizing behaviors, attention problems, and hyperactivity21-23, which are often found among children 
with attention-deficit hyperactivity disorder (ADHD)24. To our knowledge, no study has examined OPE 
exposure with clinically confirmed neurodevelopmental outcomes, such as ADHD. ADHD prevalence in 
children has more than doubled over the last decade95, surpassing 9% in the United States95 and 5% 
worldwide96. Despite the high prevalence, few non-genetic risk factors have been established as causal, 
other than lead231, 232. Although causality has not been fully established, an increasing number of studies 
point to environmental agents as potential risk factors25, 120. 
Epidemiological investigations on the modifiers of the potential relationships between OPEs and 
ADHD are even sparse. The existence of sex-specific associations has been inconsistent22, 23, and 
vulnerability by OPE metabolism has not been previously examined. OPE metabolism may involve 
enzymes such as cytochrome P450 (P450) and paraoxonase 1 (PON1)55, 60, 64, 65, whose concentrations and 
activity have been well-characterized with single nucleotide polymorphisms (SNPs) in genes77, 233-235. 
PON1 functional polymorphisms and their ability to modify the effect of organophosphate pesticide on 
neurotoxicity has been particularly well-described76, 77, 233-235, although relations with OPE exposure 
remain unclear. A better understanding of susceptible sub-populations will help in the characterization of 
OPE-related health effects. 
It is also important to consider the fact that environmental exposures often occur in mixtures, 
which has rarely been accounted for in relation to ADHD. Human exposure to some OPEs may co-occur 
with phthalates28-33, which have also been associated with ADHD25. However, due to the potential for 
these chemicals to co-occur, targeting a reduction in a specific chemical may not always be feasible. 





We undertook an investigation of OPE exposure during pregnancy and the risk of offspring 
ADHD, using a case-cohort study nested within the Norwegian Mother, Father, and Child Cohort 
(MoBa). We examined effect measure modification by child sex and polymorphisms in enzymes that are 
suspected to play a role in the metabolism of OPEs. Further, we quantified the risk of ADHD with 
elevated exposure to OPE-phthalate mixtures. 
6.3. Methods 
 Study population 
MoBa is an ongoing prospective population-based pregnancy cohort study of Norwegian-
speaking women, conducted by the Norwegian Institute of Public Health172, 205. Pregnant women were 
recruited at their routine prenatal ultrasound visit (≈17 gestational weeks) from all over Norway between 
1999 and 2008. Upon enrollment, women were asked for a urine and a blood sample after providing 
written consent179. At birth, cord blood samples were also collected. The cohort now includes 114,500 
children, 95,200 mothers, and 75,200 fathers.  
For the current study, we nested a case-cohort study within MoBa25. Eligibility criteria included 
singleton births without Down’s syndrome or cerebral palsy who were born between 2003 and 2008, and 
whose mothers donated a urine sample during pregnancy, completed the standard MoBa questionnaire 
when the child was 36 months old, and resided within close proximity to Oslo, Norway25. Among the 
eligible population, we selected participants into the case group and sub-cohort180. In a case-cohort study, 
the standard estimation of odds ratios can be interpreted as risk ratios (RRs) if the sub-cohort is selected at 
baseline irrespective of their case status. Further, restricting the case group only to cases who are not 
already sampled into the sub-cohort allows the estimation of variance using the standard formula for odds 
ratios181. The sub-cohort children were selected at baseline from the entire base population that met the 
eligibility criteria for the current study, irrespective of their ADHD case status (n=555). 
 Case group definition 
ADHD cases were identified from all MoBa enrollees eligible for the current study, by data 




and outpatient clinics in Norway, including registrations of hyperkinetic disorders by specialist health 
services (ICD-10 code: F90185). Hyperkinetic disorder is mandatorily reported in Norway236, and therefore 
individuals first diagnosed with or continuing to seek care/treatment can be identified. To exclude any 
erroneous or false diagnosis, ADHD cases were defined as having at least two registrations of 
hyperkinetic disorder. The case group was defined as ADHD cases who were not simultaneously sampled 
as part of the sub-cohort. A total of 295 identified ADHD cases were included in our case group, which 
excludes 2 children who had already been selected into the sub-cohort (n=2). 
 Exposure assessment 
Maternal urine samples were collected at 17 weeks gestation and shipped unrefrigerated to a 
central ISO-certified lab in Oslo (Biobank), where the samples were stored at -80°C206. Urinary 
concentrations of DPHP, DNBP, BBOEP, and BDCIPP were measured using ultra-performance liquid 
chromatography (UPLC) coupled with quadrupole-time-of-flight (QTOF) at the Norwegian Institute of 
Public Health, which had been validated previously in Norwegian mother-child pairs182. UPLC was first 
performed on centrifuged 5ul urine aliquots using Acquity® C18 BEH column (50mm× 2.1 mm× 1.7 μm) 
from Waters Corp. (Milford, MA, U.S.A.). The OPE metabolites were then identified and quantified with 
tandem mass spectrometry using a Xevo® G2-S QTOF from Waters (Norwegian Institute of Public 
Health, Oslo, Norway). All assays were conducted in randomized batches, each of which included 
laboratory in-house as well as laboratory-blinded pooled urine quality control samples. Specific gravity, 
as defined by the ratio of the density of urine to water, was measured in each urine sample using a pocket 
refractometer (PAL-10S), Atago.  
 Genotyping of maternal and fetal DNA 
Maternal blood samples were collected in EDTA tubes at enrollment (17 weeks gestation). 
Plasma was separated before shipment overnight to the MoBa Biobank. Immediately after birth, an 
umbilical cord blood sample was collected, shipped to the biobank, and plasma separated upon arrival. 
All samples were stored at -80°C until analysis179. Maternal and fetal DNA was extracted from blood 




selected three SNPs with established functional polymorphisms on candidate enzymes that may 
metabolize OPEs: PON1 Q192R, PON1 L55M, and CYP1A2 -1545C/T. Genotyping was conducted at the 
Norwegian University of Life Sciences (NMBU) using the Sequenom MassARRAY IPLEX® platform186.  
We included the two most common coding region polymorphisms in PON1 protein, which codes 
for amino acids 192 and 5563. Q192R refers to A>G mutation at codon 192, which results in an exchange 
of the amino acids glutamine (Q) to arginine (R) (Gln192Arg; rs662). This variant influences substrate-
specific enzymatic activities of PON1, for example, carriers of R192 have stronger PON1 enzymatic 
activity for oxon substrates such as paraoxon63, 77. L55M refers to T>A mutation at codon 55, which 
results in a leucine (L)-to-methionine (M) substitution (Leu55Met; rs854560). L55M is in linkage 
disequilibrium with rs705379 (-108C/T), and consequently, the carriers of M55 have lower PON1 
enzyme concentrations in plasma237. 
A coding region polymorphism in CYP1A2 was also examined, specifically -1545C/T 
(rs2470890). Although this is a synonymous variant that does not result in altered protein, it is in linkage 
disequilibrium with CYP1A2*1F (rs762551238), which has been associated with higher enzyme 
inducibility. In the carriers of C allele, CYP1A2 can be induced even at low exposure to a substrate, 
resulting in a quicker clearance, as has been reported for smoking73, melatonin69, and caffeine68. 
 Covariate Assessment 
Given that phthalates may share common source products as OPEs and are considered 
independent risk factors for ADHD, we considered phthalates as 1) confounders when evaluating 
individual OPEs as risk factors, and 2) part of an exposure mixture to quantify the impact of reduced joint 
exposures. Specifically, we considered 6 phthalates previously measured25, 27: monoethyl phthalate 
(MEP), mono-iso-butyl phthalate (MiBP), mono-n-butyl phthalate (MnBP), monobenzyl phthalate 
(MBzP), the molar sum of di(2-ethylhexyl)phthalate metabolites (∑DEHP), and the molar sum of di-iso-
nonyl phthalate metabolites (∑DiNP).  
We also utilized covariate data from MoBa questionnaires and via linkage with the Medical Birth 




in Norway239. From the questionnaire at 15 weeks, we obtained maternal self-reports of education, any 
depression before or during the first or second trimester of pregnancy, smoking during the first or second 
trimester of pregnancy, and alcohol intake during pregnancy. Maternal fish intake during pregnancy was 
estimated from a food frequency questionnaire that mothers completed at their 22 weeks’ gestation188. 
Briefly, pregnant women responded to a semi-quantitative questionnaire that is intended to characterize 
diet during the first four months of pregnancy via 255 food items and additional dietary supplements. 
Total fish intake was estimated by summing the daily intake of all fish types (g/day). From the 
questionnaire that mothers completed at 36-months, we obtained maternal ADHD symptoms that were 
measured using the World Health Organization Adult ADHD Self-Report Scale240. Finally, maternal age 
at delivery, parity, birth year, and child sex were obtained from MBRN. 
Since pregnancy DPHP has been previously linked with maternal thyroid disruption (paper1), a 
potential risk factor for ADHD16, 88, we additionally explored pregnancy maternal thyroid function as a 
potential mediator. Specifically, we included total thyroxine (TT4), total triiodothyronine (TT3), thyroid 
stimulating hormones (TSH), and TT3:TT4 ratio estimated from blood samples which were collected at 
the same date as the urine samples, approximately 17 weeks’ gestation (paper1). 
 Ethics Data collection for MoBa was approved by the Norwegian Data 
The establishment of MoBa and initial data collection was based on a license from the Norwegian 
Data Protection Agency and approval from The Regional Committees for Medical and Health Research 
Ethics. The MoBa cohort is now based on regulations related to the Norwegian Health Registry Act. The 
current study was approved by the Norwegian Data Inspectorate and the Norwegian Committee for 
Medical and Health Research Ethics (REC), and the Institutional Review Board at the University of North 
Carolina Chapel Hill. 
 Analytic approach 
We used descriptive statistics to characterize the distribution of exposures and covariates 
according to case-cohort status. Exposure concentrations below the limit of detection (LOD) were 




missing covariate data were imputed assuming missing at random, conditional on all other covariates, 
outcome, and exposure: sex (n = 2 missing), fish consumption (n=48), maternal ADHD symptoms 
(n=172), and maternal education (n=36). Imputation was conducted using the R package mice.  
We used directed acyclic graphs to identify minimally sufficient adjustment sets in order to 
appropriately account for confounders. These confounding sets included birth year, season of urine 
collection, maternal fish consumption during pregnancy, maternal depression before or during pregnancy, 
maternal ADHD symptoms, maternal education, and prenatal maternal phthalate concentrations. 
Specifically for phthalates, we adjusted for ∑DEHP due to its association with ADHD in the current study 
population identified in a previous study25. In addition, we considered child sex, a strong risk factor for 
ADHD. All analyses were adjusted for season of urine collection, child sex, birth year, maternal 
depression, maternal education, and log ∑DEHP. This final adjustment set was selected after considering 
the bias-variance tradeoff from the full model, where all covariates from the minimally sufficient 
adjustment set were included.  
After considering the dose-response for each OPE metabolite using quartiles of exposure, each 
OPE metabolite was coded as a binary indicator. We used the cutpoint of sub-cohort median for DPHP, 
the limit of quantification (LOQ) for DNBP, and the LOD for BBOEP and BDCIPP. We estimated RRs 
and 95% confidence intervals (CI) of ADHD using logistic regression in each imputed dataset and pooled 
the estimates using Rubin’s rule241.  
We investigated effect measure modification by child sex (alpha: 0.2), since the underlying 
mechanism of OPEs may be sex-specific as has been reported in experimental settings7, 242. We applied 
the augmented product-term approach, including product terms between child sex and all covariates, 
which is roughly equivalent to conducting a fully-stratified analysis243. Using the same approach, we also 
investigated effect measure modification by maternal and fetal genotypes. Genotypes were coded as -1 
(most common homozygote), 0 (heterozygote), and 1 (least common homozygote), and modeled 





Mediation analysis was conducted to decompose the total effect of DPHP on ADHD into a 
natural direct effect and a natural indirect effect through maternal thyroid function during pregnancy, 
using a previously published method190, 191. Briefly, the natural direct effect of DPHP on ADHD was 
defined as the RR associated with elevated DPHP while adjusting for a thyroid function biomarker and 
confounders. The natural indirect effect of DPHP on ADHD via a thyroid function biomarker was 
estimated by multiplying two estimates and then taking its exponential. These two estimates included: 1) 
log(RR) of ADHD associated with elevated thyroid function biomarker while adjusting for DPHP and 
confounders in the case-cohort, and 2) the beta coefficient from a linear regression model fitted in the 
sub-cohort with DPHP and confounders as the independent variables and the thyroid function biomarker 
as the dependent variable. The total effect was defined as the product of the natural direct and indirect 
effect. We included in each model, all confounders identified for DPHP–ADHD, DPHP–thyroid function, 
and thyroid function–DPHP relationships: maternal self-reported depression during and before pregnancy, 
education, age, dietary intakes of selenium and iodine during pregnancy, and urinary log(DEHP) during 
pregnancy, and season of bio-sample collection, parity, birth year, and child sex. Estimates were pooled 
across multiply imputed datasets using Rubin’s rules and confidence intervals were bootstrapped244. 
Since study participants are likely exposed to a mixture of chemicals, whereby reducing exposure 
to a single metabolite is not always feasible, we quantified the impact of a hypothetical intervention that 
can jointly reduce exposures to common-detect OPE-phthalate mixtures. Specifically, the marginal RRs 
of ADHD with simultaneous 1-quartile decrease of DPHP, DNBP, and 6 phthalate metabolites were 
estimated using quantile-based g computation in R using package qgcomp245. 
The current study is based on version 9 of the quality-assured data files. 
6.4. Results 
A total of 555 children were sampled into the sub-cohort, inclusive of 2 children with ADHD 
(Table 9). The case group consisted of 295 children with ADHD, who were not already selected into the 
sub-cohort. The ADHD case group, as compared to the sub-cohort, had a higher percentage of boys, 




of ADHD, mothers with education less than college, mothers with depression, and mothers who smoked 
during pregnancy. 
DPHP and DNBP were commonly detected in our study population (> 90% above the LOD), 
while BBOEP and BDCIPP were detected less frequently (Table 7). The geometric mean of urinary 
DPHP concentrations in the case group mothers was slightly higher than that in the sub-cohort mothers. 
Similar trends were observed for ∑DEHP, which have been previously reported in detail25. 
We observed an elevated risk of ADHD in relation to higher DPHP and BDCIPP exposure during 
pregnancy (Table 10). The risk of ADHD in children with maternal prenatal DPHP concentrations above 
the sub-cohort median was 1.38 times [95% CI: 0.96, 1.99] that of children with maternal pregnancy 
DPHP concentrations below the sub-cohort median. Similarly, detectable concentrations of BDCIPP 
during pregnancy was associated with an RR of 1.50 [0.98, 2.28]. Alternative exposure classification 
using quartiles did not substantially alter the interpretation (Supplemental Figure 1). Associations 
between DPHP and ADHD appeared to be somewhat stronger among girls (2.04 [1.03, 4.02]) than boys 
(1.15 [0.74, 1.80], p-interaction 0.17;Table 11). 
We also observed suggestive modification by SNPs (Figure 6). When interaction terms with 
maternal PON1 Q192R were included in the model, the RRs of ADHD associated with prenatal DPHP 
exposure was higher among the carriers of PON1 Q192R QR (1.60 [1.01, 2.54]) and PON1 Q192R RR 
(2.41 [0.94, 6.23]), with the interaction p-value of 0.19. Child’s CYP1A2 -1545C/T polymorphism also 
modified the association, with stronger associations among the carriers of CYP1A2 -1545C/T CC (4.59 
[1.38, 15.29]) and CYP1A2 -1545C/T CT (1.69 [0.89, 3.19]), with an interaction p-value of 0.02. 
However, the detection of BDCIPP and genotype CC was uncommon in the current study population, 
thus strata were sparse. Alternative genotype coding resulted in a similar relationship (Supplementary 
Figure 2). 
Given the potential for DPHP to disrupt maternal thyroid function during pregnancy 246, a risk 
factor for ADHD16, 88, we conducted an additional mediation analysis. The total effect of ADHD 




decomposed into a natural direct RR of 1.29 [0.87, 1.94] and a natural indirect RR of 1.04 [1.00, 1.10] 
through maternal TT3:TT4 ratio (12.48% mediated; Table 4).  
Since study participants are likely exposed to a mixture of OPEs and phthalates, which are 
suspected risk factors for ADHD and ADHD-like behavior, we estimated the impact of simultaneously 
reducing all constituents of a common-detect OPE-phthalate mixture. A simultaneous 1-quantile 
reduction of DPHP, DNBP, MEP, MiBP, MnBP, MBzP, ∑DEHP, and ∑DiNP was associated with an 
ADHD RR of 0.68 [0.64, 0.72].  
6.5. Discussion 
In this large, nested case-cohort study of MoBa, children born to mothers with elevated urinary 
DPHP during mid-gestation had a higher risk of ADHD. The RR for ADHD associated with greater than 
median DPHP during pregnancy was greater among female offspring than among male offspring. Part of 
this association was mediated through maternal thyroid function measured at 17 weeks gestation, 
specifically TT3:TT4 ratio. We also observed weak modified by maternal SNPs; specifically, slightly 
stronger associations were observed among children born to mothers with PON1 Q192R genotype RR or 
QR. For BDCIPP, we observed that detection, though rare, was associated with an elevated risk of ADHD 
in both sexes. We also observed modification by the child’s CYP1A2 -1545C/T genotype, where stronger 
associations were observed among children with CC and CT. However, we caution over-interpretation 
given the small number of children with CC and low detection of BDCIPP. We further quantified the 
impact of simultaneously increasing all constituents of an OPE- phthalate mixture using a quartile-based g 
computation, and estimated that per quartile increase in all exposure constituents, the risk of ADHD 
increased by 60%. This study adds to the growing literature linking prenatal exposure to organophosphate 
esters with ADHD or ADHD-like behaviors in children. 
 Prenatal DPHP and BDCIPP exposure as potential risk factors for ADHD 
We estimated elevated RRs of ADHD in children with higher than median DPHP (1.38 [0.96, 
1.99]) and detection of BDCIPP (1.50 [0.98, 2.28]). Our findings are in line with the only two prospective 




the Health Assessment of Mothers and Children of Salinas, a pregnancy cohort of a Mexican-American 
farmworker community in California, found that higher DPHP and BDCIPP was associated with slightly 
more hyperactivity and attention problems reported by teachers and/or mothers at age 723. Similarly in the 
Pregnancy, Infection and Nutrition cohort, DPHP and BDCIPP were associated with monotonically 
increasing hyperactivity, attention problems, externalizing behaviors, and overall more problematic 
behaviors in 3-year-olds22. The strongest association was observed for isopropyl-phenyl phenyl 
phosphate, which was not measured in our study. Although estimates were imprecise in both studies, in 
part due to small sample sizes (n= 227 and 310), the implicated behaviors are often found in children with 
ADHD and therefore are highly relevant to our study. The similarity in findings across these three studies 
is notable in light of their heterogeneous characteristics regarding exposure measurement (mid- vs late-
gestation), study population (farming community vs general population), years of study (1999-2008), 
child age at assessment (2.5-10 years), and outcome assessment (maternal-/parent-reported behaviors 
using standardized inventories vs clinically diagnosed ADHD).  
The existence of sex-specific effects, however, remains unclear. Castorina and colleagues did not 
observe statistically significant sex-interactions (significance level and stratum-specific estimates not 
provided). On the other hand, Doherty and colleagues reported slightly stronger associations among girls, 
for DPHP and BDCIPP exposure, although they were cautious in interpretation due to small sample sizes 
and imprecise estimates (interaction term p-values not provided). Our findings also support the hypothesis 
that girls could be more vulnerable to ADHD from DPHP exposure, which is in line with findings in 
experimental settings as well: heightened anxiety247 and hyperactivity248 have been reported in female 
rats. We, however, did not observe sexually dimorphic relationships for BDCIPP exposure. 
Several mechanisms may underlie the relationship between prenatal OPE exposure and fetal 
neurodevelopment, some of which could be sex-specific or involve maternal thyroid disruption during 
pregnancy. One of the parent compounds of DPHP, triphenyl phosphate (TPHP), is estrogenic249 and 
therefore could significantly impact the developing brain through interfering with synaptic 




disruptor7. Maternal thyroid dysfunction could critically impact fetal development12, 14, 16, 18, particularly 
during early pregnancy, when the fetus is heavily reliant on the maternal supply224. We also observed in 
mediation analysis, that the relationship between pregnancy DPHP exposure and offspring ADHD can be 
partly decomposed into a natural indirect effect that involved maternal TT3:TT4 ratio at 17 weeks 
gestation. The percent mediated, however, was small; which suggests that a larger portion is mediated 
through a lagged effect on maternal thyroid function or through mechanisms other than maternal thyroid 
disruption during pregnancy. Alternatively, OPEs or their metabolites may cross the placenta93, 94 and 
directly affect fetal brain development by influencing neuronal cell replication and differentiation19, 242.   
 Modification by maternal and fetal genotypes 
The relationship between prenatal DPHP exposure and childhood ADHD was weakly modified 
by maternal PON1 Q192R in our study. Since Q192R is known to affect substrate-specific PON1 
activity252, it is possible that DPHP and/or some of its parent compounds are substrates for PON1. We did 
not observe evidence of modification by PON1 L55M, which is known to affect the concentration of 
PON1 in peripheral blood77, 233-235. PON1 L55M, however, is an imperfect proxy for PON1 concentrations 
in peripheral blood253) and therefore measurement of PON1 enzyme itself in blood could yield different 
results. The interpretation of gene-environment interaction is further complicated by the fact that DPHP 
can derive from multiple parent compounds such as resorcinol bis-diphenyl phosphate50, ethylhexyl 
diphenyl phosphate49, and TPHP49, 56. Further epidemiological and experimental investigations using 
various biomarkers for DPHP parent compounds and additional measures of candidate enzymes will help 
elucidate the metabolism of OPEs and identify susceptible subpopulations. We also did not observe 
evidence of modification by corresponding fetal genotypes, possibly due to 1) immature fetal xenobiotic-
metabolizing system or 2) limited power since DNA was available from fewer children. 
While we observed substantial BDCIPP effect measure modification by fetal CYP1A2 -1545C/T, 
we caution over-interpretation of findings and acknowledge that further research is needed to confirm this 
relationship. A chance finding could arise from sparse strata, given the infrequent detection of BDCIPP, 




the metabolism of numerous exogenous factors66, which can be correlated with prenatal BDCIPP 
exposure and thus bias the relationship. It is also possible that the modification by fetal CYP1A2 observed 
in this study, is instead reflecting modification of postnatal BDCIPP exposure. Although some studies 
report the existence of enzyme in fetal liver, hepatic clearance is immature in fetuses compared to adults 
and CYP1A2 is hardly detected until after infancy254, 255. Also, BDCIPP has been reported to have 
relatively high intra-class correlation coefficients (ICC; 0.48-0.704, 43, 52, 256-258), which suggests stability of 
exposure over time. Therefore, our measurement of prenatal concentrations could be correlated with 
postnatal concentrations through continued exposure to source products that are common to mothers and 
babies. 
 Prenatal exposure to OPE-phthalate mixture and offspring ADHD 
Since we are likely exposed to multiple environmental exposures simultaneously, increased 
attention has been placed on exposure mixtures259, 260. Multiple statistical approaches to environmental 
mixtures have been developed to address different aspects of a complex exposure, and therefore it is 
critical to specify the question and purpose of analyzing exposure mixtures in order to identify the optimal 
analytic tool. We sought to answer a public health-oriented question: what is the overall impact of 
increased exposure to multiple correlated environmental triggers? This question is distinct from 
identifying a specific metabolite or synergistic/antagonistic relationships across metabolites, and the 
answers can be intuitively interpreted and often directly mapped onto the effects of potential public health 
interventions245. In this study, we utilized quantile based g-computation245 to examine the public health 
impact of simultaneous increases in the OPE-phthalate mixture and found a substantial increase in the risk 
of ADHD in relation to a 1-quartile decrease in exposure to all OPE-phthalate mixture constituents 
(DPHP, DNBP, and 6 phthalate metabolites mixture RR: 0.68 [0.64, 0.72]). Quantile based g-
computation was applied given its computational efficiency compared to BKMR and reduced bias for 
joint exposure-response relative to weighted quantile sums approach; furthermore, it is not subject to 
issues of exposure transformation given the preservation of rank-orders in quantized exposure. The 




that are targeted to jointly reduce multiple exposures, for example, cleaning more frequently to reduce 
exposure to contaminated house dust or intervening on another common consumer source of exposure. 
Further investigation of various intervention scenarios could be particularly useful since targeting a 
reduction in a specific chemical may not always be feasible. 
We note that the impact of simultaneously increasing OPE-phthalate mixture could be larger in 
other populations since our study population had low DPHP exposure (median: 0.51 ng/mL) compared to 
the previous studies of pregnant women (0.77-2.94 ng/mL; Supplementary Table 4). Additionally 
BDCIPP, another potential neurotoxicant, was not included in the quantile based g-computation due to 
limited detection (74-79%<LOD). Overall, the high RRs of ADHD observed with increasing exposure to 
OPE-phthalate mixtures in this population-based study, is in line with and summarizes the 
neurodevelopmental impacts of individual OPE and phthalate metabolites reported previously22, 23, 25, 155, 
166, 167, 261-263, calling for a timely need to take action to reduce exposure at a population level.  
 Strengths and limitations 
Our investigation was uniquely positioned to evaluate prenatal OPE exposure as a risk factor for 
clinical ADHD, leveraging an existing study that was nested in a large prospective study. As such, we 
were able to utilize the existing measures of phthalate exposure and well-characterized, prospective 
covariate data. Nesting our case-cohort study within a population-based pregnancy cohort and obtaining 
clinical diagnoses through linkage with a population-based registry enabled us to examine associations 
with a clinically diagnosed developmental disability, ADHD. Further, we took advantage of the large 
sample size and explored important potential modifiers, such as child sex and polymorphisms in genes 
suspected to play a role in the metabolism of OPEs. We also provide evidence for OPE metabolites 
infrequently studied in epidemiological investigations, i.e., DNBP and BBOEP. Another advantage of our 
study is in the consideration of phthalates to estimate 1) the individual association of OPE metabolites as 
well as 2) the impact of combined exposure to phthalates and OPEs. Lastly, this is the first study to be 





Our investigation was limited to a single spot urine sample collected at 17 weeks’ gestation, 
which may not be reflective of pregnancy-wide exposures due to the short half-lives of OPEs. However, 
OPEs are included in consumer products that people use on a daily basis. Ubiquitous exposure to OPE 
sources is expected to result in relatively stable concentrations, at least in the short term. For repeat-
samples collected over several hours to weeks, moderate ICCs ranging from 0.43 to 0.70 have been 
reported for DPHP4, 52, 256, 257; although the ICCs across studies were more variable in the long term9, 11, 34, 
43, 52, 256. 
Another limitation is in the potential for inaccuracies in ADHD case diagnoses registered in the 
NPR. Although the NPR captures around 90% of ADHD cases in Norway236, false-positive cases may 
also be included97 due to the absence of a gold standard clinical assessment for ADHD diagnosis. The 
ADHD diagnostic criteria are based on a constellation of behavioral symptoms evaluated by clinical 
providers100, and therefore diagnosis and treatment vary by the clinical practice and the experience of the 
provider264. We attempted to remove erroneous or false registrations by limiting our cases to those that 
had more than one registration of ADHD in the NPR. Moreover, the relationships between NPR ADHD 
diagnosis status and parental reported ADHD symptoms at ages 3 and 5 using the Child Behavior 
Checklist (CBCL) and Conners Parent Rating Scale have been previously investigated265. Oerbeck and 
colleagues found that ADHD symptoms substantially predicted later NPR ADHD diagnosis (hazard ratio 
for CBCL at age 5 = 10.30, 95% CI: 7.44, 14.26). These data support the congruence of parent-reported 
symptoms of ADHD in MoBa questionnaires with later registration of ADHD within the NPR. In 
addition, any outcome misclassification as a result of inaccuracies in diagnosis in childhood would not be 
expected to be differential by maternal OPE exposure during pregnancy.  
Lastly, DPHP is a biomarker that lacks specificity and is reflective of exposures to multiple 
parent compounds such as resorcinol bis-diphenyl phosphate50, ethylhexyl diphenyl phosphate49, and 
TPHP49, 56. If only a subset of DPHP parent compounds exhibits thyroid disrupting properties, the 
associations estimated with DPHP may not accurately reflect that of the thyroid active compound. 




an integrated marker will be beneficial to quantify the adverse impact of DPHP-related exposures.  
 Public health implications 
Although ADHD is one of the most common psychiatric disorders in children266, 267, few 
modifiable risk factors for ADHD have been identified. We found that prenatal exposure to DPHP and 
BDCIPP may be associated with an increased risk of ADHD, and that girls may be particularly vulnerable 
to DPHP exposure. Exposures to OPEs, though prevalent, are modifiable through the implementation of 
population-wide regulatory policies, voluntary removal of these chemicals from consumer products, or 
behavioral interventions. Since population exposure to OPEs has been shown to be steadily increasing48, 
there is an urgent need to take action to reduce subsequent health effects of exposure. 
6.6. Conclusion 
DPHP and BDCIPP exposure during pregnancy may increase the risk of ADHD in offspring. 
Combined exposure to common-detect OPE and phthalates resulted in a substantial increase in ADHD 
risk. For DPHP, the relationship varied by child sex and maternal PON1 Q192R polymorphisms and we 





6.7. Tables and Figures 
Table 9 Descriptive characteristics of the study population by ADHD case-cohort status. 






Maternal age at birth Mean ± sd (missing) 29.2 ± 5.08 (2) 30.9 ± 4.22 (2) 
ADHD status Identified as an ADHD case 
from NPR 
295 (100) 2 (< 0.01) 
Not identified as an ADHD 
case from NPR 
0 (0)  553 (100) 
Sex Boy 211 (72.0) 275 (49.7) 
 Girl 82 (28.0) 278 (50.3) 
Birth year 2003-2004 130 (44.1) 56 (10.1) 
 2005 87 (29.5) 130 (23.4) 
 2006 44 (14.9) 194 (35.0) 
 2007-2008 34 (11.5) 175 (31.5) 
Parity Nulliparous 140 (47.8) 271 (49.0) 
 Multiparous 153 (52.2) 282 (51.0) 
Maternal education > College completed 25 (9.4) 169 (30.8) 
 College completed 74 (27.8) 238 (43.4) 
 < College completed 158 (59.4) 125 (22.8) 
 Other 9 (3.4) 16 (2.9) 
Maternal ADHD symptoms Indicative of ADHD (SRS≥4) 11 (8.1) 21 (3.9) 
(Self-Report Scale, SRS) Not indicative of ADHD 
(SRS<3) 125 (91.9) 522 (96.1) 
Maternal depression 
(any before/during pregnancy) 
Reported any 44 (14.9) 34 (6.1) 
Did not report any  251 (85.1) 521 (93.9) 
Fish intake during pregnancy ≥340g per week  33 (13.0) 60 (11.0) 
reported at 22 weeks gestation 
(recommended by 268) 
227-340g per week 
(recommended) 44 (17.3) 112 (20.4) 
<227g per week 177 (69.7) 376 (68.6) 
Prenatal smoking  Yes 93 (34.7) 79 (14.4) 
 No 175 (65.3) 470 (85.6) 
Prenatal alcohol intake Yes 26 (10.9) 66 (12.9) 
 No 212 (89.1) 445 (87.1) 
Month of urine  May – August 121 (41.0) 183 (33.0) 
sample collection September – November 56 (19.0) 121 (21.8) 
 December – April 118 (40.0) 251 (45.2) 
Abbreviations: ADHD, attention deficit hyperactivity disorder; NPR, Norwegian patient registry; DPHP, 
diphenyl phosphate; DNBP, di-n-butyl phosphate; BBOEP, bis(2-butoxyethyl) hydrogen phosphate; 
BDCIPP, bis(1,3-dichloro-2-propyl) phosphate; GM, geometric mean; SE, geometric standard error; 
LOD, limit of detection; DEHP, di(2- ethylhexyl) phthalate.  
 
 
Table 10 Descriptive characteristics of environmental exposures in the current study, by case-cohort status. 
OPE LOD LOQ 
Case group (N=295)  Sub-cohort (N=555) 
>LOD >LOQ GM ± SD 
Percentiles 
 >LOD >LOQ GM ± SD 
Percentiles 
25th 50th 75th 25th 50th 75th 
DPHP 
 (µg/L) 
0.03 0.1 98.0% 93.3% 0.70 ± 2.80 0.40 0.71 1.25  96.8% 90.5% 0.52 ± 2.77 0.29 0.52 0.97 
DNBP 
 (µg/L) 
0.07 0.2 93.6% 54.2% 0.26 ± 2.06 0.16 0.24 0.4  93.9% 54.9% 0.28 ± 2.27 0.17 0.25 0.42 
BBOEP 
 (µg/L) 
0.07 0.2 55.2% 12.1% 0.08 ± 2.44 <LOD 0.08 0.15  51.8% 8.6% 0.09 ± 2.38 <LOD 0.08 0.15 
BDCIPP 
 (µg/L) 
0.17 0.5 25.9% 10.8% 0.20 ± 2.48 <LOD <LOD 0.3  21.2% 12.6% 0.23 ± 2.83 <LOD <LOD <LOD 
Note: All OPEs standardized for specific gravity and concentrations <LOD substituted for LOD/√2 for the calculation of GM and SD. 
Abbreviations: DPHP, diphenyl phosphate; DNBP, di-n-butyl phosphate; BBOEP, bis(2-butoxyethyl) hydrogen phosphate; BDCIPP, bis(1,3-
dichloro-2-propyl) phosphate; GM, geometric mean; SE, geometric standard error; DEHP, di(2-ethylhexyl)phthalate; LOQ, limit of quantification; 







Table 11 Risk ratios (RR) of ADHD from a case-cohort study using binary exposure, pooled across multiply imputed datasets (m=20). 
OPE Cutoff (µg/L) 



















63% 49%  
1.38 (0.96, 1.99) 
 
2.04 (1.03, 4.02) 
 




LOQ (0.20) 54% 55%  
0.88 (0.62, 1.26) 
 
0.77 (0.42, 1.44) 
 




LOD (0.07) 55% 52%  
1.03 (0.73, 1.46) 
 
1.15 (0.62, 2.13) 
 




LOD (0.17) 26% 21%  
1.50 (0.98, 2.28) 
 
1.52 (0.77, 3.02) 
 
1.55 (0.90, 2.65) 
0.97 
Note: Model1 adjusted for birth year, child sex, maternal education, maternal depression, maternal urinary log(DEHP), and the season of urine 
collection. Model2 additionally included sex interaction terms between all covariates. DPHP, diphenyl phosphate; DNBP, di-n-butyl phosphate; 
BBOEP, bis(2-butoxyethyl) hydrogen phosphate; BDCIPP, bis(1,3-dichloro-2-propyl) phosphate; DEHP, di(2-ethylhexyl)phthalate; LOQ, limit of 








Figure 6. Risk ratios (RRs) of ADHD using binary OPE exposure, stratified by genotypes. This figure shows the RRs and corresponding 95% 
confidence intervals of ADHD stratified by maternal (square) or fetal (circle) genotypes of three different genes (PON1 Q192R, PON1 L55M, and 






6.8. Supporting materials 
 
Supplementary Figure 5 Risk ratios of attention-deficit hyperactivity disorder associated with increased 
organophosphate ester exposure based on binary classification (primary analysis) or quartiles, pooled across 
multiply imputed datasets (m=20; 295 cases; 555 sub-cohort).  
Abbreviations: 
Q1, 0-25th percentile; Q2, 25-50th percentile; Q3, 50-75th percentile; Q4, 75-100th percentile; DPHP, 




Supplementary Figure 6. Risk of attention-deficit hyperactivity disorder in children with prenatal organophosphate ester exposure above threshold 
relative to those below the threshold, stratified by amino acid/genotype coded with an additive (continuous) or general (categorical) model. 
Abbreviations: DPHP, diphenyl phosphate; DNBP, di-n-butyl phosphate; BBOEP, bis(2-butoxyethyl) hydrogen phosphate; BDCIPP, bis(1,3-






Supplementary Table 3 Frequencies (%) of maternal and fetal amino acids/genotype by case and cohort 
status 
Gene SNPs (rs#) Amino acids/ 
Genotype 
Case group   Sub-cohort  
Maternal gene Fetal gene  Maternal gene Fetal gene 
PON1 Q192R Missing 20 123  17 127 
 (rs662) QQ 127 (46%) 75 (43%)  290 (54%) 238 (56%) 
  QR 120 (43%) 82 (47%)  209 (39%) 161 (38%) 
  RR 30 (11%) 17 (10%)  39 (7%) 29 (7%) 
 L55M Missing 15 122  19 127 
 (rs854560) LL 125 (44%) 83 (47%)  216 (40%) 189 (44%) 
  LM 128 (45%) 77 (44%)  256 (48%) 197 (46%) 
  MM 29 (10%) 15 (9%)  64 (12%) 42 (10%) 
CYP1A2 -1545C/T Missing 19 122  16 129 
 (rs2470890) TT 113 (41%) 71 (41%)  216 (40%) 163 (38%) 
  TC 122 (44%) 72 (41%)  255 (47%) 208 (49%) 




Supplementary Table 4 Comparison of the median concentrations (µg/L) of urinary DPHP, BDCIPP, DNBP, and BBOEP observed among the sub-
cohort mothers in the current study with previous reports (specific gravity adjusted geometric mean in parenthesis). 
Population Author, 
year 




















 43 59 2014-
2015 
RI, US 29.5 ± 4.5 12 0.86 1.09 . . 
28 1.06 1.39 . . 
 44 23 2015 Shanghai, 
China 
(25-40) 2nd trimester 0.83 1.58 . . 




(18-45) 2-3rd trimester 2.94 0.26 . <0.08 
 46  349 2001-
2006 





 23 310 1999-
2000 


























NJ, US (18-) . (1.9) (2.4) . . 













US (6-) . 0.89 0.82 0.24 . 
Abbreviations: 
DPHP, diphenyl phosphate; DNBP, di-n-butyl phosphate; BBOEP, bis(2-butoxyethyl) hydrogen phosphate; BDCIPP, bis(1,3-dichloro-2-propyl) 
phosphate; SD, standard deviation. 
 







CHAPTER 7. CONCLUSION 
 
7.1.  Summary of Findings 
Human exposure to OPEs has increased over the past two decades. Increasing exposure trends 
raise concerns as recent studies of OPEs suggest both endocrine disruptive and neurotoxic properties. In 
this dissertation, potential health effects of OPE exposure during pregnancy were investigated, 
specifically with regards to thyroid function disruption in mothers and ADHD in offspring. A case-cohort 
study was nested within a large, well-characterized pregnancy cohort, MoBa. This allowed a cost-efficient 
investigation of metabolites from common-use OPEs, utilizing a rich body of covariates and considering 
important modifiers that have not been previously examined.  
 Limited evidence of thyroid disruption by exposure to OPEs during pregnancy 
In Specific Aim 1, we observed limited evidence of association to support potential thyroid 
disruption of pregnancy OPE exposures. Although in conventional models, we observed potential thyroid 
disruption by DPHP, such associations were attenuated towards near-null in BKMR. Rather, we observed 
that ∑DiNP was consistently associated with differences in thyroid function biomarkers in both the 
conventional and BKMR models. Specifically, pregnant women with ∑DiNP concentration in the 75th 
percentile had a 0.37 ng/µg [95% credible interval: -0.59, -0.15] lower TT3:TT4 ratio compared to those 
in the 25th percentile when using GLM; while the association was slightly larger using BKMR (exact: -
0.48 ng/µg [-0.96, 0.003]; approx.: -0.57 ng/µg [-0.90, -0.24]; PIP: 0.869). The observed associations 
with TT3:TT4 ratio could be suggestive of a thyroid disruption mechanism distinct from hyper- or hypo-
active stimulation of the thyroid gland. Such thyroid hormonal imbalance may have been missed if the 
outcome biomarker did not include TT3:TT4 ratio, since the associations with TT3 and TT4 were not 
notable, although divergent in directionality. 
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 DPHP & BDCIPP during pregnancy as risk factors for offspring ADHD  
 In Specific Aim 2, greater than sub-cohort median DPHP and detectable BDCIPP during 
pregnancy were associated with elevated risk of ADHD in offspring (DPHP RR: 1.38 [95% CI: 0.96, 
1.99]; BDCIPP RR: 1.50 [0.98, 2.28]). For DPHP, we observed weak mediation through maternal thyroid 
function during pregnancy and suggestive evidence of effect measure modification by child sex and 
functional polymorphisms in candidate enzymes for OPE metabolism. Specifically, higher DPHP during 
pregnancy affected more greatly girls (2.04 [1.03, 4.02]) and children born to mothers with PON1 Q192R 
QR (1.69 [0.89, 3.19]) or PON1 Q192R RR (4.59 [1.38, 15.29]) genotypes (interaction term p-value: 
0.19). Detectable concentrations of BDCIPP during pregnancy did not show sex-specific associations but 
more greatly affected children who carried C allele of CYP1A2 -1545C/T (CC RR: 4.59 [1.38, 15.29]; CT 
RR: 1.69 [0.89, 3.19]; p: 0.02), although cautious interpretation is needed due to the small number of 
children with CYP1A2 -1545C/T genotype CC. Given the correlated nature of OPEs and phthalates, we 
quantified the impact of a hypothetical intervention where combined exposure to frequently-detected 
OPEs (i.e., DPHP & DNBP) and all phthalate metabolites were reduced by 1 quartile, which resulted in a 
RR of 0.68 [0.64, 0.72]. 
 Results from supplementary analyses 
Several additional analyses were conducted in this dissertation to support the primary findings, 
which included the consideration of exposure in alternative forms. For Aim 1, the impact of specific 
gravity standardization, batch effect, and effect measure modification by dietary iodine and SNPs were 
additionally explored. For Aim 2, the primary analysis was repeated using a conventional case-control 
sampling scheme and considering alternative definitions of an OPE-phthalate mixture.  
The functional forms of OPEs were alternatively assessed using quantile-based categories for 
both aims. Monotonic dose-response was observed between DPHP and the TT3:TT4 ratio (Appendix 
Figure 1; Appendix Figure 2), which supports the use of a continuous variable in the primary analysis. 
Although deciles of exposure were not monotonically associated with TT3:TT4 ratio, the overall shape of 
the relationship was similar to that from quartiles of exposure. The risk of ADHD also increased with 
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exposure quartiles, although the RR of the highest quartile was similar to that of the second-highest 
quartile, lending support to the use of binary exposure indicator in the primary analysis (Appendix Figure 
3). Additionally for Aim 2, similar but reduced associations were observed when exposure was 
characterized using a linear term (Appendix Figure 3) or using a binary indicator based on the lower 
tertile reported in the only other study of non-agricultural population, PIN (Appendix Table 1; Appendix 
Figure 4).  
In an additional analysis for Specific Aim 1, the impact of specific gravity standardization was 
examined using specific gravity unadjusted concentrations. In this alternative approach, specific gravity 
was included in models as an adjustment variable or ignored completely. The individual dose-response of 
OPEs remained similar to the primary analysis, regardless of how specific gravity was considered in the 
model, although their posterior inclusion probabilities varied (Appendix Figure 5-Appendix Figure 7).  
Since Specific Aim 1 utilized continuous exposure concentrations with flexible modeling, the 
results could be susceptible to exposure measurement error. We examined the QC samples (Appendix 
Figure 8-Appendix Figure 11) and further explored potential batch effects using a leave-one-out 
approach, where the primary analysis was repeated with successive removal of one analytic batch at a 
time. When the leave-one-out approach was applied to BKMR, the overall shape of the dose-response and 
interpretation of DPHP and DNBP remained similar to that from the primary analysis (Appendix Figure 
12-Appendix Figure 23). 
Lastly, SNPs and dietary iodine were explored as modifiers given their potential role in OPE 
metabolism77, 233-235 and thyroid homeostasis217, 218, respectively. The results, however, did not support 
these factors as modifiers (Appendix Figure 24; Appendix Figure 25). 
In Specific Aim 2, as an alternative to the case-base sampling employed in the primary analysis, 
the analysis was repeated using a conventional case-control approach. Controls were selected from the 
population at risk at the time of case identification through NPR data linkage. In this alternative scheme, 
the case group included all children with ADHD (n=297) and the sub-cohort included all children without 
ADHD (n=553), as opposed to the primary analyses where all randomly sampled children irrespective of 
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their ADHD status were in the sub-cohort (n=555) and the case group included all children with ADHD 
who were not already selected into the sub-cohort (n=295). The odds ratios from the case-control analysis 
were similar to the RRs from the primary analysis (Appendix Table 2), which was expected due to the 
low prevalence of ADHD (<10%).  
Although studies of ADHD-like behaviors report multiple phthalate metabolites may influence 
fetal neurodevelopment155, 166, 167, 261-263, the specific phthalate metabolite associated with clinical ADHD is 
limited to DEHP25. Since the impact of jointly increasing exposure mixture would vary by the definition 
of an exposure mixture, the primary analysis was repeated using narrower (only including DEHP) and 
broader (including secondary metabolites of DEHP) definitions of a mixture. The RR of ADHD 
associated with 1 quartile increase in all mixture components varied by the definition of mixtures, but the 
estimates were similar to that of primary analysis with overlapping confidence intervals (Appendix Figure 
28). 
7.2. Discussion and interpretation of findings 
 DPHP- and BDCIPP-related exposures as developmental toxicants 
Taken together, the results from the primary and supplementary analysis support the hypothesis 
that higher DPHP and BDCIPP exposure during pregnancy could increase the risk of ADHD in offspring; 
with maternal thyroid disruption as a weak potential mediator. 
Although the level of uncertainty varied with the type of statistical method applied, we observed 
in conventional models of Aim1 that pregnancy DPHP was associated with altered maternal thyroid 
function, a potential mechanism underlying offspring ADHD development. It is noteworthy that the 
thyroid disruptive relationship was not apparent using the individual thyroid function biomarkers as 
dependent variables, but became evident when TT3:TT4 ratio was examined. This may suggest an 
alternative underlying mechanism, that is distinct from overall hyper- or hypo-activation of the thyroid 
gland. Elevated TT3:TT4 ratio, i.e., higher TT3 per µgTT4, can be observed when thyroxine to 
triiodothyronine conversion rate increases in peripheral cells215, 216 or if triiodothyronine excretion rate 
increases in the thyroid gland due to iodine deficiency or hyperactive thyroid217-219. Both mechanisms are 
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plausible since over 70% of the current study population have low iodine intake, and experimental 
evidence of DPHP-related exposures are in support of both mechanisms6, 7. Such underlying mechanisms 
may in part explain why previous studies of thyroid function have reported small and inconsistent 
associations9-11, 85, 86, together with additional differences in the study populations such as sex, pregnancy 
status, and euthyroid status. 
The findings of elevated risk of ADHD in Aim 2 may be evidence that DPHP and BDCIPP, or 
their parent compounds, are developmental neurotoxicants. Consistent with these findings, slightly more 
attention problem, hyperactivity, and/or externalizing behaviors have been observed in children with 
elevated DPHP or BDCIPP in maternal urine during pregnancy, reported in two pregnancy cohorts: 
farmworker community in California23 and pregnant women seeking prenatal care from UNC hospital in 
North Carolina22. The commonalities in findings across studies are noteworthy, since the two previous 
studies and the current study are heterogeneous in exposure measurement (mid- vs late-gestation), study 
population (farming community vs general population), years of study (1999-2008), locations (California, 
USA; North Carolina, USA; Oslo, Norway), child age (2.5-7 years), and outcome assessment tools 
(maternal-/parent-reported behaviors vs physician-diagnosed disorder). Abnormal behaviors in response 
to prenatal DPHP or BDCIPP exposure is not limited to human populations, and have also been observed 
in experimental settings using zebrafish20, 247, 248, 269, 270 and rodent models247, 248. Experimental studies have 
also found estrogenic249, thyroid disruptive7, 12, 14, 16, 18, and neurotoxic19, 242, 249 properties for some OPEs. 
Hormonal imbalance caused by OPEs could critically impact fetal neurodevelopment given that the 
development and organization of neurons are influenced by sex steroids250, 251, 271 and thyroid hormones147, 
272. Thyroid imbalance of women during early pregnancy could particularly impact the developing fetus, 
since thyroid glands are not mature in fetuses and they rely heavily on the maternal supply224. 
Alternatively, OPEs or their metabolites may cross the placenta93, 94 and interfere with the hormonal 
system in the fetuses or directly influence their developing brain.  
Another important aspect of these results is that the associations were observed at quite low levels 
of exposure. BDCIPP was detected in only 21% of the sub-cohort, and the sub-cohort median DPHP 
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(0.51µg/L) was 1.5 to 5 order of magnitude lower than that reported in pregnant women around the globe 
(Supplementary Table 2)23, 43-46, including PIN and CHAMACOS. The associations observed even in low 
concentrations raises concerns for the future population, who will be exposed to higher concentrations of 
OPEs due to the increasing exposure trends1, 48. Despite the low-level exposures, this dissertation may 
have been able to identify links between prenatal DPHP and neurodevelopment by utilizing a clinically 
confirmed diagnosis of hyperkinetic disorder from a population-based patient registry, which restricted 
the ADHD case group to children with at least two registrations of hyperkinetic disorder. It is certainly 
possible that DPHP and BDCIPP exposures during pregnancy impact fetal neurodevelopment, resulting in 
a spectrum of altered behaviors. Further investigation using a broader definition of ADHD and detailed 
characterization of subtypes, as well as other neurodevelopmental endpoints, will contribute to 
quantifying the neurodevelopmental impacts of OPE exposure during pregnancy. 
 Conducting research with mixtures perspectives 
In addition to the primary findings regarding maternal thyroid function and offspring ADHD, 
both aims incorporated approaches to consider the correlated nature of xenobiotic exposures. We are 
simultaneously exposed to mixtures of environmental agents, whether it be due to multiple chemicals 
included in a single source product; individual-level behavioral patterns that predispose individuals to a 
cluster of source products; behavioral patterns specific to sub-populations sharing commonalities in 
occupation, socioeconomic status, culture; or population-wide structural patterns arising from industrial 
trends in chemical applications or governmental regulations. Such correlations among environmental 
agents have long been a motivating methodological challenge for environmental epidemiology. The 
mixture methods toolbox has rapidly expanded in recent years, resulting in a plethora of analytic 
approaches that enable researchers to tackle exposure mixtures from various perspectives. However, there 
is not a one-size-fits-all approach to handling correlated exposures, with each approach having different 
assumptions and answering different questions. Therefore, it is crucial to first define the research 




Four types of primary research questions have been identified in the previous literature and are 
summarized in Table 12273-275. In this dissertation, the independent effects of mixture components were 
examined using multivariable linear regression and BKMR in Aim 1 and the overall effect of mixture 
components was explored using quantile based g-computation in Aim 2. The following section includes 
discussions of questions relevant to BKMR and quantile based g-computation, and additionally 
demonstrate a question to identify patterns of mixture compositions. 
Table 12 Research questions that can be asked in the context of environmental mixtures 
 Primary question Sub-questions 
1 What are the independent 
effects of mixture 
components? 
 Which components contribute to the outcome? 
 Which components do not contribute to the outcome? 
 How much does each component contribute to the outcome? 
 What is the dose-response for each mixture component? 
2 Is there interaction across 
mixture components? 
 Which components interact? 
 Is the interaction synergistic/antagonistic? 
3 What is the overall effect of 
a mixture? 
 What is the net change in outcome relative to combined 
exposure? (using an aggregate index for exposure) 
 What is the net change in outcome when all mixture 
components increase by equal unit? 
4 What are the patterns of 
mixture composition? 
 On average, which mixture components travel together? 
 What are the sub-populations that share similar mixture 
composition? 
 
When one or more compounds within a mixture are so-called “bad actors” that contribute to the 
development of an outcome, a bad actor can confound the relationship between the outcome and other 
correlated chemicals, creating spurious associations for the confounded chemicals (Figure 7). Therefore, a 
research question to identify the effects of individual mixture components cannot be addressed using a 
conventional model that includes only the main pollutant of interest. Rather, co-pollutant adjustment is 
needed, which can be accomplished by simply adding multiple pollutants into the main model in the 
absence of multicollinearity. Or if the strengths of correlations among pollutants demand more complex 




Figure 7 An example of correlated exposures (X1-X3), of which only a subset (X2-X3) are true risk factors. 
A bad actor (X3) confounds a non-bad actor (X2) and as well as other bad actors (X2), resulting in biased 
estimates. 
BKMR is designed to identify a few out of many correlated chemicals, whose variability in 
concentrations most strongly predicts the variability in outcome. In addition to the identification of bad-
actor from variable selection, researchers can compare the strength of associations across chemicals. 
Another advantage in BKMR is the flexible modeling approach used to predict a dose-response curve for 
each mixture component, considering interactions between chemicals. However, it should be cautioned 
that even with such flexible modeling, skewed exposure can result in distorted dose-response curves. For 
example, Aim 1 of this dissertation demonstrated that the individual dose-response curve was not always 
consistent when BKMR was conducted in original form, after log-transformation, or standardization 
(Supplementary Figure 3). Interestingly, centering or the choice of log base did not strongly influence the 
individual shapes. Rather, changes in the ranges across exposures impacted the dose-response as well as 
the relative importance of individual chemicals in the current study population (Appendix Figure 26) and 
NHANES (Appendix Figure 27). Additional limitations of BKMR include high computational expenses, 
convergence issues particularly when covariates are not normally-distributed continuous variables, and 
complications in the interpretation and presentation of findings.  
The identification of a bad-actor from such statistical methods can help policy-makers identify 
and prioritize chemicals to undergo regulations, however, there are caveats to relying solely on statistical 
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analysis to identify bad actors. Each statistical model bears different assumptions, which may or may not 
be relevant to real-life settings. Even when the most relevant model is utilized, there is always a 
possibility of model misspecification as well as epidemiological sources of bias arising from unmeasured 
confounding, differential measurement error by correlated exposures, and selection of study participants. 
Further, an unbiased estimate may not always reflect the biological strength of a relationship, and may 
merely be due to numerical variability in exposure and outcome274. 
Rather than asking which mixture components contribute to the outcome, a researcher could be 
interested in quantifying the contribution of the overall mixture to the outcome. Such estimation can be 
easily carried out using Bayesian approaches, since unobserved, posterior distributions can be modeled 
through Bayesian analysis, for example using BKMR or quantile based g-computation274. In Aim 2 of this 
dissertation, quantile based g-computation was used to estimate the overall impact of a mixture in a case-
cohort study, which is not available in BKMR since the analysis of case-cohort studies is not supported 
by the package. A major advantage of quantile based g-computation is that intuitive and easily 
interpretable results are captured by summarizing the joint effect of a quantile increase in mixture 
components, similar to the weighted quantile sum approach but relaxing the directional homogeneity 
assumption276. Further, non-linear dose-response functions can be allowed between the quantiles of 
exposure mixture and outcome, although the forms are limited to a polynomial function. Another 
advantage is in its computational simplicity, which yielded an effect estimate comparable to BKMR in an 
additional analysis for Aim 1, although slightly more imprecise than the estimates from BKMR that 
allowed variable selection (Appendix Figure 32). Unlike BKMR, quantile based g-computation is free 
from issues of exposure transformation since the rank-order of exposure concentrations remain consistent 
regardless of the means of exposure transformation. Quantile based g-computation, however, was not 
designed to identify a bad-actor within a mixture, therefore it is not well-suited to answer questions 
regarding variable selection, characterization of individual dose-response, and dimension reduction. More 
broadly, quantifying the health impacts of an overall mixture should be interpreted with caution since the 
mixture components measured by a researcher is only a subset of all true mixture, and therefore may or 
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may not contain the truly toxic component. Further, the number of chemicals constituting the mixture and 
their relative levels vary widely by populations. Even within a population, heterogeneity would exist by 
sub-groups that share similar behavioral patterns and predispose them to specific mixture constituents. It 
was demonstrated in Aim 2 that the impact of exposure mixture varied by the definition of the exposure 
mixture (Appendix Figure 28). Therefore, the interpretation of health effects associated with an overall 
increase in exposure mixture should be made in the context of mixture definition and population 
characteristics. 
Less common in the epidemiological literature, but relevant in mixtures analysis, is a focus on 
exposure profiles. There may exist sub-groups that share similar exposure profiles, for example, due to 
similarities in socio-cultural characteristics or occupation. The identification of such sub-population can 
be carried out with algorithms such as K-means or latent class analysis. In an additional analysis of Aim 
1, K-means was conducted to identify sub-groups with similar exposure profiles, which resulted in a high-
exposure cluster and low-exposure cluster (Appendix Figure 33). Such characterization of exposure 
clusters could help to identify individuals that share common sources of exposure, however, it should also 
be cautioned that the number of clusters and the determinants of group membership could vary by study 
population with respect to sample size, sociodemographics, and the number of measured contaminants. 
As demonstrated above and in previous literature273-275, a diversity of relevant mixture-based 
questions can be asked. Therefore, it is crucial that researchers clearly specify their question, and then 
choose the analytic approach that is best suited to answer it. Despite the diversity of analytic approaches 
available, there are still unresolved but important methodological issues in analyzing mixtures. For 
example, laboratory measurement error may vary within and across chemical species, as well as their 
half-lives, relevant confounders, threshold of toxicity, and feasibility for intervention. Further, methods 
more geared toward informing policy-makers and the general population are urgently needed. While most 
policy regulations are centered around individual chemicals, there are increasing calls to utilize a class-
based approach for regulation of chemical families like organophosphate pesticides277. Therefore, a cross-
talk is needed between researchers and policymakers, not only to identify ways to incorporate mixture 
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analysis findings to inform the current single-pollutant focused policies, but also to shift and improve 
from single-pollutant focused policies to class-focused policies. 
7.3. Limitations 
 Single spot urine measure of OPE metabolites 
In this dissertation, OPE exposures during early pregnancy were estimated using single spot urine 
collected at a mothers’ ultrasound visit. A single spot urine sample may not approximate an individual’s 
average exposure over a time-interval when 1) it is not a first-void urine sample; 2) the half-life of the 
compound of interest is short; 3) the time interval of interest is wide; or 4) individual’s exposure pattern 
show strong temporal variability. Given that OPEs have short half-lives and this dissertation utilized bio-
specimens collected from convenience-sampling, the OPE metabolite concentrations observed in this 
dissertation could over or underestimate the true average concentrations of an individual, depending on 
their time to recent peak exposures. Nevertheless, the narrow time interval of urine collection (17-18 
gestational weeks) and moderate ICC reported within short time-intervals (Table 13) allows inference for 
early pregnancy OPE exposures using the observed DPHP and BDCIPP. Interpretations of DNBP and 
BBOEP are limited due to the lack of information on ICCs.  
Another limitation may arise from the inter-personal variability in time and date of urine 
collection. Internal levels of OPEs may vary by season and time of day11, due to temporal variations in 
human behaviors (e.g., ventilation and time-activity patterns) and exposures from point sources (e.g., rate 
of vaporization). Therefore, the OPE metabolite concentrations detected in urine may have differential 
measurement error with respect to season and time of urine collection. The season of urine collection was 
considered as a confounder in this dissertation, however, the time of bio-sample collection was not due to 
the lack of available data. Although the time of bio-sample collection does not likely confound the 
relationship between pregnancy OPE exposure and offspring ADHD, it could confound the relationship 




Table 13 Intraclass correlation coefficients of DPHP and BDCIPP reported in previous studies 
Study N Region Year Time interval DPHP BDCIPP BBOEP DNBP 
Pregnant women   
256 8 NC, US 2011-
2012 
18th gestational weeks 























43 54 RI, US 2014-
2015 





Subfertile females   
52 211 MA, US 2005-
2015 
Across cycles  
(178 days apart) 
(0.34) (0.56) . . 
Within a cycle  
(7.6 days apart) 
(0.53) (0.48) . . 
Mothers   
257 48 Norway 1-5, 
2012 







Women and men   
11 52 MA, US 2010-
2011 
All participants 0.19 
(0.13) 
. . . 
Restricted to the same 
season (1-year span) 
0.39 
(0.21) 
. . . 
4 19 NY, US 2018 3-day intervals for 5 









Men   













 Non-specificity of DPHP to TPHP 
As noted previously, DPHP has multiple parent OPEs from which it can originate49. Therefore, 
elevated urinary DPHP concentrations could be due to high exposures to TPHP, other parent metabolites, 
or direct exposure to DPHP. Since multiple exposure scenarios can result in elevated urinary DPHP, it is 
not feasible to pinpoint the parent OPE that could have driven the associations between DPHP and 
ADHD or thyroid function. Nevertheless, DPHP can be seen as a non-specific marker for exposures to 
any OPEs that can be metabolized into DPHP. Further, if DPHP is the toxic metabolite compared to other 
metabolites that are more specific to one parent compound, the current investigation will be able to pick 
up strong signals and call for further investigations in future studies. 
 Cross-sectional analysis of OPE-thyroid function relationship 
For Specific Aim 1, plasma biomarkers of maternal thyroid function were measured on the same 
day that mothers provided their urine samples. The close temporal proximity between blood and urine 
sample collection allowed the investigation of exposure and outcome that both have short half-lives. 
However, thyroid function in women fluctuates widely over pregnancy208, 209, hence the potential thyroid-
disruption at different gestational weeks or lagged-effect of exposure was not possible from the current 
investigation. Future investigation using repeat-samples of DPHP and thyroid function within and across 
days will be helpful to fully characterize DPHP-related exposure’s impact on maternal thyroid function 
during pregnancy. 
 Validity of ADHD diagnosis 
This dissertation defined eligible MoBa children as ADHD based on two or more registrations of 
hyperkinetic disorders (ICD-10), identified from the NPR. Two potential sources of outcome 
misclassification are possible. 
The first possibility stems from the temporal misalignment between two data sources: MoBa and 
NPR registry. The NPR registry data is only available from 2008 while the birth years of eligible MoBa 
enrollees range from 2003-2008 (Appendix Figure 29). For example, if a child born in 2003 had two 
registrations of ADHD before 2008 but did not receive treatment or care since 2008, this child will be 
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missed as an ADHD case. Even though ADHD defined by ICD-10 is thought to have an early onset, 
usually in the first 5 years of life185, ADHD diagnosis under the age 6 is rare236, as supported by the 
previous guideline which states that children should be screened for ADHD from age 6 through 12101. 
Further, children with two registrations of ADHD before the age of 5 will likely be asked to come in for 
follow-up visits and continue with treatment, in which case they will be registered in the system as 
ADHD cases. Therefore, the number of missed ADHD cases is expected to be small. Furthermore, the 
sub-cohort was sampled at baseline irrespective of their ADHD status and therefore eliminates the 
potential misclassification of ADHD-free controls. The potential impact of birth years was additionally 
examined by estimating stratified RRs using an augmented product-term approach, which did not show 
strong evidence of heterogeneity by birth year (Appendix Figure 30-Appendix Figure 31).  
The other point of ADHD misclassification may arise from the quality of the medical records in 
the NPR. Although NPR is expected to capture around 90% of ADHD cases in Norway236, false-positive 
cases may be included97. This is in part due to the absence of a gold standard clinical assessment tool for 
the diagnosis of ADHD. ADHD diagnostic criteria are evaluated using a constellation of behavioral 
symptoms by clinical providers100, whose experience and clinical practice strongly influence diagnosis 
and treatment264. To remove erroneous or false registrations, this dissertation defined ADHD as children 
with 2 or more registrations in the NPR. Moreover, the sensitivity of NPR-identified ADHD cases is 
likely high, as demonstrated by Oerbeck265. They found that NPR ADHD diagnosis was strongly 
predicted by ADHD symptoms at ages 3 and 5, evaluated with the Conners Parent Rating Scale and Child 
Behavior Checklist (CBCL; hazard ratio at age 5 = 10.30, 95% CI 7.44, 14.26). Additionally, any 
outcome misclassification as a result of inaccuracies in ADHD diagnosis in childhood would not be 
expected to be differential by maternal OPE exposure during pregnancy. 
7.4. Public Health Significance 
This dissertation responds to the urgent need to understand the potential adverse health impacts of 
OPE exposure, given the steadily increasing OPE production and population-level exposure. Although the 
effect sizes observed in this dissertation were small to moderate, the concentrations of OPE metabolites in 
 
104 
this study population is lower than that of contemporary Americans due to earlier years of enrollment 
(2003-2008). As OPE exposures are widespread and increasing over time, the neurotoxic influence of 
OPEs identified in this dissertation could have a substantial impact on public health, if causal. Further 
investigations are needed to fully characterize the health impacts of OPEs. Since exposures to OPE 
exposure is modifiable through behavioral change and population-wide policies, results from current and 
future investigations could collectively inform population-wide policies to reduce OPE exposures, 
particularly during pregnancy. Such efforts to intervene on environmental exposures may help reduce the 
burden of ADHD that can be attributed to OPE exposures during pregnancy. Since ADHD is a common 
neuropsychiatric disorder among children, entailing costly health and economic burden, even a small 
reduction in ADHD risk could have an important impact on public health. 
7.5. Concluding remarks on chemical regulation 
The increasing production and population-wide concentrations of OPEs despite the unknown 
safety level are concerning in light of toxicological and epidemiological evidence of harm. Although 
OPEs do not persist in the environment as the conventional chemical it replaced, PBDEs, it cannot be said 
that such substitution is without health consequences. Chemical substitutions in the absence of safe 
alternative chemical(s) have also been observed previously with the case of BPA to BPS substitution278. 
Further alarming is that such patterns of chemical substitution are increasingly reported47, 279, 280. The 
vicious cycle of regrettable substitution could continue if the current platform of chemical regulations 
remains unchanged. In America, common-use chemicals that can cause “unreasonable risk to human 
health and the environment” are removed from the market and replaced with novel alternatives, under the 
Toxic Substances Control Act (TSCA)281. TSCA, however, does not mandate toxicity testing of new 
chemicals, which often result in substitutions with novel chemicals that are structurally and functionally 
similar to the legacy chemicals under regulation. Therefore, a legacy to novel chemical substitution can 
result in similar or even worse adverse health effects, hence regrettable substitution.  
A step to sustainable chemical regulation could start by mandating thorough toxicity testing of 
new chemicals, prior to allowing entry into the market, followed by further mitigation and adaptation 
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efforts. Mitigation efforts could involve the identification of safe replacement chemicals, whether it be 
through re-evaluations of existing but less-commonly used chemicals with similar desirable chemical 
properties or through the development of new safe alternative chemicals. Once a safe alternative has been 
identified, removal of the conventional chemical from the market is desirable. Such process, however, can 
be lengthy since careful considerations are needed to formulate and implement a population-wide policy. 
Complete eradication of exposure will take an even longer time, since exposure can still occur from pre-
existing products in households. Therefore, strategic adaptation approaches are needed in parallel with the 
mitigation approaches, to regulate, not completely ban, the concentrations in source products to the levels 
that are absolutely necessary. Further efforts are needed to identify vulnerable life stages and sub-
populations as well as their exposure reduction strategies through education and behavioral interventions.  
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APPENDIX: SUPPLEMENTAL MATERIALS 
 
  
Appendix Figure 1 Relationship between DPHP and thyroid function biomarkers using exposure 





Appendix Figure 2 Relationship between DNBP and thyroid function biomarkers using exposure 








Appendix Table 1 Distribution of DPHP and BDCIPP in the current study and the previous study using 
PIN. 
 Current study  PIN Study 22 
 LOD Q1 Median Q3 
%<NC tertile 1 




DPHP 0.03µg/L 0.31 0.54 1.01 81% 85%  
0.127-
0.243pg/L 
0.80 1.38 2.37 
BDCIPP 0.17µg/L <0.17 <0.17 0.16 97% 97%  
0.136-
0.333pg/L 






Appendix Figure 4 Risk ratios of ADHD using binary classification of DPHP (original: sub-cohort median 





Appendix Figure 5 Absolute difference in thyroid function biomarkers associated with increasing an 
individual metabolite from its 25th to 75th percentile (green: specific gravity standardized; orange: 
specific gravity included in model; purple: specific gravity unadjusted/unstandardized), while keeping 
other metabolites constant at their 25th percentiles and adjusting for year, dietary iodine, selenium, parity, 





Appendix Figure 6 Individual dose-response using specific gravity unstandardized concentrations, 
adjusting for specific gravity, year, dietary iodine, selenium, parity, depression, season, education, age, 
and smoking. In each plot, the posterior inclusion probability is denoted on the bottom-right corner and 
exposure percentiles are indicated with vertical lines (orange: 25th; purple: 50th; and green: 75th; BKMR 





Appendix Figure 7 Individual dose-response using specific gravity unadjusted/unstandardized 
concentrations, adjusting for year, dietary iodine, selenium, parity, depression, season, education, age, and 
smoking. In each plot, the posterior inclusion probability is denoted on the bottom-right corner and 
exposure percentiles are indicated with vertical lines (orange: 25th; purple: 50th; and green: 75th; BKMR 









































Appendix Figure 11 Box plot of DNBP concentrations in pooled urine samples by analytic batch (original 





Appendix Figure 12 Leave-one-batch-out analysis using BKMR: absolute difference in total thyroxine 
(µg/dL) associated with increasing the log-transformed concentrations of an individual metabolite from 
the 25th to the 75th percentile while keeping other metabolites constant at their 25th percentile and 
adjusting for dietary iodine, selenium, parity, depression, season, education, age, and smoking during 





Appendix Figure 13 Leave-one-batch-out analysis using BKMR: absolute difference in total 
triiodothyronine (ng/dL) associated with increasing the log-transformed concentrations of an individual 
metabolite from the 25th to the 75th percentile while keeping other metabolites constant at their 25th 
percentile and adjusting for dietary iodine, selenium, parity, depression, season, education, age, and 





Appendix Figure 14 Leave-one-batch-out analysis using BKMR: absolute difference in thyroid stimulating 
hormone (mU/L) associated with increasing the log-transformed concentrations of an individual metabolite 
from the 25th to the 75th percentile while keeping other metabolites constant at their 25th percentile and 
adjusting for dietary iodine, selenium, parity, depression, season, education, age, and smoking during 




Appendix Figure 15 Individual dose-response with total thyroxine (TT4) from leave-one-out analysis 




Appendix Figure 16 Individual dose-response with total thyroxine (TT4) from leave-one-out analysis 




Appendix Figure 17 Individual dose-response with total thyroxine (TT4) from leave-one-out analysis 




Appendix Figure 18 Individual dose-response with total triiodothyronine (TT3) from leave-one-out 




Appendix Figure 19 Individual dose-response with total triiodothyronine (TT3) from leave-one-out 




Appendix Figure 20 Individual dose-response with total triiodothyronine (TT3) from leave-one-out 




Appendix Figure 21 Individual dose-response with thyroid stimulating hormone (TSH) from leave-one-




Appendix Figure 22 Individual dose-response with thyroid stimulating hormone (TSH) from leave-one-




Appendix Figure 23 Individual dose-response with thyroid stimulating hormone (TSH) from leave-one-




Appendix Figure 24 Relationships between thyroid function biomarkers in maternal plasma and 





Appendix Figure 25 Relationship between thyroid function biomarkers in maternal plasma and 






Appendix Figure 26 Detailed comparison of exposure transformation methods on the influence of 
individual dose-response curves for triiodothyronine (T3) using BKMR: original form; scaled by 
interquartile range (IQR), centered by median and scaled by IQR, centered by mean and scaled by 
standard deviation (SD), log2 transformed, ln transformed, log10 transformed (BKMR results extracted 




Appendix Figure 27 Influence of exposure transformation on the relationship between total 
triiodothyronine (T3) and urinary measures of environmental chemicals (phthalates, parabens, and 
phenols) among adolescents (<20 years) in the National Health and Nutrition Examination Survey, using 









Appendix Table 2 Risk ratios of ADHD from logistic regression with case-base (primary analysis) or 
conventional case-control analysis (cases defined as all ADHD children; controls defined as all non-cases). 
Metabolite Threshold 
Case-subcohort analysis  
[primary analysis] 
(case group n=295;  
sub-cohort n=555) 
 
Conventional case-control analysis 
(case group n=297; 
sub-cohort n=553) 




1.38 (0.96, 1.99)  1.41 (0.98, 2.04) 
DNBP LOQ 0.88 (0.62, 1.26)  0.88 (0.62, 1.25) 
BBOEP LOD 1.03 (0.73, 1.46)  1.06 (0.75, 1.51) 












Appendix Figure 29 Illustration of the years of follow-up by birth year, and ADHD diagnosis observable 
windows. 
Due to the misalignment between MoBa birth years (2003 - 2008) and NPR data (2008 – 2014), 
the age windows for which “ADHD diagnosis is observable” vary by birth year (orange-shaded). 
Since study participants were born between 2003 and 2008 but the NPR is only available starting 
2008, there will be “potentially missed cases” up to the age of 5 (grey-shaded). However, the number of 
potentially missed cases is expected to be negligible given that 1) ADHD is rarely diagnosed before the 
age of 5236 and 2) two or more registrations are required to satisfy the ADHD case definition in the current 
dissertation. Even if an individual’s initial diagnosis fell under the window for “potentially missed ADHD 
cases”, the individual would still be registered into NPR and identified as an ADHD case if the individual 
did not withdraw from MoBa and continued to seek care/treatment during the window for “ADHD 
diagnosis observable”.  
Second, the NPR data linkage was conducted mid-2014 for births occurring 2003-2008, therefore 
an administrative right censoring at varying age depending on birth year. Due to this administrative 
censoring, some participants meeting the ADHD case definition between the ages 6 and 11 will not be 
captured (yellow-shaded). For example, ADHD cases born 2003 will be reflective of incident cases 
during the first 11 years of life, while ADHD cases born 2008 will be reflective of incident cases during 





Appendix Figure 30 Birth-year specific risk ratios estimated with an augmented product-term approach in 




Appendix Figure 31 Birth-year specific risk ratios estimated with an augmented product-term approach in 






Appendix Figure 32 Changes in total triiodothyronine (TT3) by increasing all continuous exposure from 
their 25th percentiles, modeled with quantile based g-computation (black) and BKMR (red: with variable 





Appendix Figure 33 OPE and phthalate metabolites and thyroid function biomarkers distributions by 
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